

Department of Oncology Annual Report 2014 Publications

Sharon Abish

1. Siminoski K, Lentle B, Matzinger MA, Shenouda N, Ward LM; Canadian **STOPP Consortium**. Observer agreement in pediatric semiquantitative vertebral fracture diagnosis. *Pediatr Radiol*. 2014 Apr;44(4):457-66. doi: 10.1007/s00247-013-2837-4. Epub 2013 Dec 10.
2. Essa M, Santo AE, Fleming A, Mitchell D, **Abish S**. Exploring the attitudes of pediatric oncologists toward the use of laxatives for the prevention of constipation in patients undergoing active treatment: a Canadian perspective. *Pediatr Hematol Oncol*. 2014 Aug;31(5):448-57. doi: 10.3109/08880018.2013.837129. Epub 2013 Oct 2.
3. Phan V, Blydt-Hansen T, Feber J, Alos N, Arora S, Atkinson S, Bell L, Clarson C, Couch R, Cummings EA, Filler G, Grant RM, Grimmer J, Hebert D, Lentle B, Ma J, Matzinger M, Midgley J, Pinsk M, Rodd C, Shenouda N, Stein R, Stephure D, Taback S, Williams K, Rauch F, Siminoski K, Ward LM; **Canadian STOPP Consortium**. Skeletal findings in the first 12 months following initiation of glucocorticoid therapy for pediatric nephrotic syndrome. *Osteoporos Int*. 2014 Feb;25(2):627-37. doi: 10.1007/s00198-013-2466-7. Epub 2013 Aug 16.

Bassam Abdulkarim

1. Lecavalier-Barsoum M*, Quon H, **Abdulkarim B**. Adjuvant treatment of anaplastic oligodendrogliomas and oligoastrocytomas. Invited review. *Cochrane Database Syst. Rev*. 2014 May 15; 5:CD007104. [Epub ahead of print] PMID: 24833028.
2. Karen Jung*, Fang Wu, Peng Wang, Xiaoxia Ye, **Bassam S Abdulkarim** and Raymond Lai. YB-1 regulates Sox2 to coordinately sustain stemness and tumorigenic properties in a phenotypically distinct subset of breast cancer cells. *BMC Cancer*. May 9, 2014, 14:328 doi:10.1186/1471-2407-14-328.
3. Boychak A, Bauman G, Fisher B, **Abdulkarim S Bassam**, Amanie J, Fulton D, Murtha A, Patel S, Urtasun R, Ghosh S, Roa WH. A Phase I Study of Tomotherapy in Patients With Primary Benign and Low-grade Brain Tumors: Late Toxicity and Quality of Life. *Am J Clin Oncol*. 2014 Jan 22. [Epub ahead of print]

Jason Agulnik

1. Albanna AS, Kasymjanova G, Robitaille C, Cohen V, Brandao G, Pepe C, Small D, **Agulnik J**. Comparison of the yield of different diagnostic procedures for cellular differentiation and genetic profiling of non-small-cell lung cancer. *J Thorac Oncol*. 2014 Aug;9(8):1120-5. doi: 10.1097/JTO.0000000000000230.
2. Esfahani K, **Agulnik JS**, Cohen V. A Systemic Review of Resistance Mechanisms and Ongoing Clinical Trials in ALK-Rearranged Non-Small Cell Lung Cancer. *Front Oncol*. 2014 Jul 21;4:174. doi: 10.3389/fonc.2014.00174. eCollection 2014. Review.

Moulay Alaoui Jamali

1. Morand GB, da Silva SD, Hier MP, **Alaoui-Jamali MA**. Insights into genetic and epigenetic determinants with impact on vitamin D signaling and cancer association studies: the case of thyroid cancer. *Frontiers Oncology* 2014 Nov 4;4:309-315.

2. Xiao D, Chen S, Shao Q, Chen J, Bijian K, Laird DW, **Alaoui-Jamali** MA. Dynamin 2 interacts with connexin 26 to regulate its degradation and function in gap junction formation. *Int J Biochem Cell Biol.* 2014 Oct; 55:288-97.
3. Gupta A, Lacoste B, Pistel PJ, Ingram DK, Hamel E, **Alaoui-Jamali** MA, Szarek WA, Vlahakis JZ, Jie S, Song W, Schipper HM. Neurotherapeutic effects of novel HO-1 inhibitors in vitro and in a transgenic mouse model of Alzheimer's disease. *J Neurochem.* 2014 Dec;131(6):778-90.
4. Xu B, Teng LH, Silva SD, Bijian K, Al Bashir S, Jie S, Dolph M, **Alaoui-Jamali** MA, Bismar TA. The significance of dynamin 2 expression for prostate cancer progression, prognostication, and therapeutic targeting. *Cancer Med.* 2014 Feb;3(1):14-24 (corresponding author).
5. Silva SD, **Alaoui-Jamali** MA, Hier M, Soares FA, Graner E, Kowalski LP. Cooverexpression of ERBB1 and ERBB4 receptors predicts poor clinical outcome in pN+ oral squamous cell carcinoma with extranodal spread. *Clin Exp Metastasis.* 2014 Mar;31(3):307-16.
6. da Silva SD, **Alaoui-Jamali** MA, Soares FA, Carraro DM, Brentani HP, Hier M, Rogatto SR, Kowalski LP. TWIST1 is a molecular marker for a poor prognosis in oral cancer and represents a potential therapeutic target. *Cancer.* 2014 Feb 1;120(3):352-62. (corresponding author).

Thierry Alcindor

1. Judson I, Verweij J, Gelderblom H, Hartmann JT, Schöffski P, Blay JY, Kerst JM, Sufliarsky J, Whelan J, Hohenberger P, Krarup-Hansen A, **Alcindor T**, Marreaud S, Litière S, Hermans C, Fisher C, Hogendoorn PCW, Paolo dei Tos A, van der Graaf W. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first line treatment of advanced or metastatic soft tissue sarcoma: A randomised Phase 3 trial. *Lancet Oncology.* 2014 15(4): 415-423. doi: 10.1016/S1470-2045(14)70063-4. March 2014 [Epub ahead of print]
2. Ringash J, Au HJ, Shapiro JD, Jonker DJ, Zalberg JR, Moore MJ, Strickland A, Kotb RR, Jeffery M, **Alcindor T**, Ng S, Salim M, Sabesan S, Easaw J, Shannon J, El-Tahche F, Walters I, Tu D, O'Callaghan CJ. Quality of life in K-RAS WT colorectal cancer: the CO.20 phase III randomized trial. *Cancer.* 2014 Jan 15;120(2):181-9 2013 Oct 11. doi: 10.1002/cncr.28410. [Epub ahead of print]
3. Cools-Lartigue J, Jones D, Spicer J, Zourikian T, Rousseau M, Eckert E, **Alcindor T**, Vanhuysse M, Asselah J, Ferri LE. Management of Dysphagia in Esophageal Adenocarcinoma Patients Undergoing Neoadjuvant Chemotherapy: Can Invasive Tube Feeding be Avoided? *Annals of Surgical Oncology.* 2014 Dec 5. [Epub ahead of print]
4. **Alcindor T**. Response of refractory Ewing sarcoma to pazopanib. *Acta Oncologica* 2014 Oct 27:1-2. [Epub ahead of print]

Raquel Aloyz

1. Niazi MT, Mok G, Heravi M, Lee L, Vuong T, **Aloyz R**, Panasci L, Muanza T. Effects of dna-dependent protein kinase inhibition by NU7026 on dna repair and cell survival in irradiated gastric cancer cell line N87. *Curr Oncol.* 2014 Apr;21(2):91-6. doi: 10.3747/co.21.1509.

Armen Aprikian

1. Santos F, Zakaria AS, Kassouf W, Tanguay S, **Aprikian AG**. High hospital and surgeon volume and its impact on overall survival after radical cystectomy among patients with bladder cancer in Quebec. *World Journal of Urology*, Dec 4, 2014
2. Sanyal C, **Aprikian AG**, Cury F, Chevalier S, Dragomir A. Clinical management and burden of prostate cancer a Markov Monte-Carlo model. *PloS One*, 9(12):Dec4, 2014
3. Abou-Haidar H, Abourbih S, Braganza D, Qaoud TA, Lee L, Carli F, Watson D, **Aprikian AG**, Tanguay S, Feldman LS, Kassouf W. Enhanced recovery pathway for radical prostatectomy implementation and evaluation in a universal healthcare system. *Canadian Urology Association Journal*, 8:418-23, 2014
4. Santa Mina D, Matthew AG, Hilton WJ, Au D, Awasthi R, Albhai SM, Clarke H, Ritvo P, Trachtenburg J, Fleshner NE, Finelli A, **Aprikian AG**, Tanguay S, Carli F. Prehabilitation for men undergoing radical prostatectomy for prostate cancer: a multicentre pilot randomized controlled trial. *BMC Surgery*, Nov 13, 2014
5. Barayan GA, **Aprikian AG**, Hanley J, Kassouf W, Brimo F, Begin LR, Tanguay S. Outcome of repeated prostate biopsy during active surveillance: implications for focal therapy. *World Journal of Urology*, Nov 12, 2014
6. Zakaria A, Santos F, Dragomir A, Tanguay S, Kassouf W, **Aprikian AG**. Postoperative mortality and complications after radical cystectomy for bladder cancer in Quebec: A population-based analysis during the years 2000-2009. *Canadian Urology Association Journal*, 8(7):259-267, 2014
7. Klotz L, Drachenburg D, Singal R, **Aprikian AG**, Fradet Y, Kebabjian M, Zarenda M, Chin J. An open-label phase 2 trial of bicalutamide dose escalation from 50 mg to 150 mg in men with CAB and castration resistance. *Prostate Cancer and Prostatic Diseases*, 17(4), 320-4, 2014
8. Xu B, Chevarie-Davis M, Chevalier S, Scarlata E, Zeizoun N, Dragomir A, Tanguay S, Kassouf W, **Aprikian AG**, Brimo F. The prognostic role of ERG immunopositivity in prostatic adenocarcinoma: a study including 454 cases and review of the literature. *Human Pathology*, 45(3), 488-97, 2014
9. Bachir BG, **Aprikian AG**, Izawa J, Chin J, Fradet Y, Fairey A, Estey E, Jacobsen N, Rendon R, Cagiannos I, Lacombe L, Lattouf JB, Kapoor A, Matsumoto E, Saad F, Bell D, Black P, So A, Drachenbur D, Kassouf W. Effect of body mass index on the outcomes of patient with upper tract cancers treated with radical surgery: results of a Canadian multicentre collaboration. *Urologic Oncology*, 32(4), 441-8, 2014
10. Santos F, Dragomir A, Kassouf W, Franco E, **Aprikian AG**. Predictors of preoperative delays before radical cystectomy for bladder cancer in Quebec: a population-based study. *British Journal of Urology International*, March 24, 2014
11. Barayan G, Brimo F, Begin LR, Hanley JA, Liu Z, Kassouf W, **Aprikian AG**, Tanguay S. Factors influencing disease progression of prostate cancer under active surveillance: a McGill University Health Centre cohort. *British Journal of Urology International*, Mar 13, 2014
12. Bachir BG, Dragomir A, **Aprikian AG**, Tanguay S, Fairey A, Kulkarni G, Breau RH, Black PC, Kassouf W. Contemporary cost-effectiveness analysis comparing sequential BCG and electromotive mitomycin versus BCG alone for patients with high-risk non-muscle invasive bladder cancer. *Cancer* 120 (16), 2424-31, 2014

13. Alrabeeah K, Alkhayal M, **Aprikian AG**, Bladou F. Robotic assisted radical nephrectomy for renal angiomyolipoma with vena caval thrombus extension. *Urologic Annals* 6(2), 176-8, 2014.
14. Chevarie Davis M, Riazalhosseini Y, Arsenault M, **Aprikian AG**, Kassouf W, Tanguay S, Latour M, Brimo F. The morphologic and immunohistochemical spectrum of papillary renal cell carcinoma: study including 132 cases with pure type 1 and 2 morphology as well as tumors with *American Journal of Surgical Pathology*, 38(7) 887-94, 2014
15. Brimo F, Xu B, Scarlata E, Begin LR, Spatz A, Solomon L, Zakaria A, Leung K, Ploussard G, Bladou F, Kassouf W, Tanguay S, Chevalier, **Aprikian AG**. Biopsy characteristics in men with a preoperative diagnosis of prostatic adenocarcinoma with high Gleason score (8-10) predict pathologic outcome in radical prostatectomy. *Human Pathology* July 2, 2014
16. Dragomir A, Dinea D, Vanguyse M, Cury F, **Aprikian AG**. Drug costs in the management of castrate resistant metastatic prostate cancer in Canada. *BMC Health Services Research* 14:252, 2014
17. Patel N, Souhami L, Manusre JJ, Duclos M, **Aprikian AG**, Faria S, David M, Cury F. PSA bounce after high-dose rate prostate brachytherapy and hypofractionated external beam radiotherapy. *Brachytherapy*, July 9, 2014.
18. Zakaria A, Haddad R, Dragomir A, Kassouf W, Andonian S, **Aprikian AG**. Royal College surgical objectives of urologic training: a survey of faculty members from Canadian training programs. *Canadian Urology Association Journal*, 8:167, 2014
19. Yafi F, Brimo F, Steinberg J, **Aprikian AG**, Tanguay S, Kassouf W. Prospective analysis of specificity and sensitivity of urinary cytology and other urinary biomarkers for bladder cancer. *Urologic Oncology*, Jul 15, 2014
20. Dragomir A, Cury F, **Aprikian AG** Active surveillance for low-risk prostate cancer compared with immediate treatment: a Canadian cost comparison. *Canadian Medical Association Journal Open*, April 24, 2014

Sarit Assouline

1. Nielsen TH, Diaz Z, Christodoulopoulos R, Charbonneau F, Qureshi S, Rousseau C, Benlimame N, Camlioglu E, Constantin AM, Oros KK, Krumsiek J, Crump M, Morin RD, Cerchietti L, Johnson NA, Petrogiannis-Halioitis T, Miller WH Jr, **Assouline SE**, Mann KK. Methods for sample acquisition and processing of serial blood and tumor biopsies for multicenter diffuse large B-cell lymphoma clinical trials. *Cancer Epidemiol Biomarkers Prev*. 2014 Dec;23(12):2688-93. doi: 10.1158/1055-9965.EPI-14-0549.
2. **Assouline S**, Culjkovic-Kraljacic B, Bergeron J, Caplan S, Cocolakis E, Lambert C, Lau CJ, Zahreddine HA, Miller WH Jr, Borden KL. A phase I trial of ribavirin and low-dose cytarabine for the treatment of relapsed and refractory acute myeloid leukemia with elevated eIF4E. *Haematologica*. 2015 Jan;100(1):e7-9. doi: 10.3324/haematol.2014.111245.
3. Kuruvilla J, **Assouline S**, Hodgson D, MacDonald D, Stewart D, Christofides A, Komolova M, Connors J. A Canadian evidence-based guideline for the first-line treatment of follicular lymphoma: joint consensus of the Lymphoma Canada Scientific Advisory Board. *Clin Lymphoma Myeloma Leuk*. 2015 Feb;15(2):59-74. doi:10.1016/j.clml.2014.07.015. Epub 2014

4. Damlaj M, **Assouline S**. Is there a role for omacetaxine in the management of chronic myelogenous leukemia in the era of the tyrosine kinase inhibitors? *Leuk Lymphoma*. 2015 Jan;56(1):6-7. doi: 10.3109/10428194.2014.918972. Epub 2014 Jun 25. No abstract available.
5. Zahreddine HA, Culjkovic-Kraljacic B, **Assouline S**, Gendron P, Romeo AA, Morris SJ, Cormack G, Jaquith JB, Cerchiatti L, Cocolakis E, Amri A, Bergeron J, Leber B, Becker MW, Pei S, Jordan CT, Miller WH, Borden KL. The sonic hedgehog factor *GLI1* imparts drug resistance through inducible glucuronidation. *Nature*. 2014 Jul 3;511(7507):90-3. doi: 10.1038/nature13283. Epub 2014 May 28.
6. Gambacorti-Passerini C, Brümmendorf TH, Kim DW, Turkina AG, Masszi T, **Assouline S**, Durrant S, Kantarjian HM, Khoury HJ, Zaritskey A, Shen ZX, Jin J, Vellenga E, Pasquini R, Mathews V, Cervantes F, Besson N, Turnbull K, Leip E, Kelly V, Cortes JE. Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up. *Am J Hematol*. 2014 Jul;89(7):732-42. doi: 10.1002/ajh.23728. Epub 2014 Apr 28.
7. Fanale M, **Assouline S**, Kuruvilla J, Solal-Céligny P, Heo DS, Verhoef G, Corradini P, Abramson JS, Offner F, Engert A, Dyer MJ, Carreon D, Ewald B, Baeck J, Younes A, Freedman AS. Phase IA/II, multicentre, open-label study of the CD40 antagonistic monoclonal antibody lucatatumumab in adult patients with advanced non-Hodgkin or Hodgkin lymphoma. *Br J Haematol*. 2014 Jan;164(2):258-65. doi: 10.1111/bjh.12630. Epub 2013 Nov 13.

Laurent Azoulay

1. Fox BD*, **Azoulay L**, Dell'Aniello S, Langleben MD, Lapi F, Benisty J, Suissa S. The use of antidepressants and the risk of idiopathic arterial hypertension. *Can J Cardiol* 2014 Oct 2;30(12):1633-1639.
2. Fournier JP*, Win H, Yu OH, **Azoulay L**. Metformin and low levels of thyroid-stimulating hormone in patients with type 2 diabetes mellitus. *CMAJ* 2014 Oct 21;186(15):1138-45.
3. Assayag J*, Pollak MN, **Azoulay L**. Post-diagnostic use of beta-blockers and the risk of death in patients with prostate cancer. *Eur J. Cancer* 2014 Nov;50(16):2838-45.
4. Courand S*, **Azoulay L**, Dell'Aniello S, Suissa S. Cardiac Glycosides use and the risk of lung cancer: A nested case-control study. *BMC Cancer* 2014 Aug 8;14:573.
5. Couraud S*, Dell'Aniello S, Bouganim N, **Azoulay L**. Cardiac glycosides and the risk of breast cancer in women with chronic heart failure and supraventricular arrhythmia. *Breast Cancer Res Treat*. 2014 Aug;146(3):619-26.
6. Bensimon L*, Yin H, Suissa S, Pollak MN, **Azoulay L**. The use of metformin in patients with prostate cancer and the risk of death. *Cancer Epidemiol Biomarkers Prev*. 2014 Oct;23(10):2111-8.
7. Matok I*, **Azoulay L**, Yin H, Suissa S. Immortal time bias in observational studies of drug effects in pregnancy. *Birth Defects Res A Clin Mol Teratol*. 2014 Sept;100(9):658-62.
8. **Azoulay L**, Dell'Aniello S, Simon TA, Renoux C, Suissa S. Initiation of warfarin in patients with atrial fibrillation: early effects on ischaemic strokes. *Eur Heart J* 2014;21;35(28):1881-7.
9. Thombs BD, Arthurs E, Coronado-Montoya S, Roseman M, Delisle VC, Leavens A, Levis B, **Azoulay L**, Smith C, Ciofani L, Coyne JC, Feeley N, Gilbody S, Schinazi J, Stewart DE, Zekowitz P. Depression screening and patient outcomes in pregnancy or postpartum: a systematic review. *J Psychosom Res*. 2014;76(6):433-46.

10. Faillie JL*, **Azoulay L**, Patenaude V, Hillaire-Buys D, Suissa S. Incretin based drugs and risk of acute pancreatitis in patients with type 2 diabetes: cohort study. *BMJ* 2014;348:g2780.
11. Khalaf D, Hilton JF, Clemons M, **Azoulay L**, Yin H, Vandermeer L, Dent S, Hopkins S, Bouganim N. Investigating the discernible and distinct effects of platinum-based chemotherapy regimens for metastatic triple-negative breast cancer on time to progression. *Oncol Lett* 2014;7(3):866-870.
12. Bensimon L*, Yin H, Suissa S, Pollak MN, **Azoulay L**. Type 2 diabetes and the risk of mortality among patients with prostate cancer. *Cancer Causes Control* 2014;25(3):329-38.
13. Chukkapalli S, Amessou M, Dilly AK, Dekhil H, Zhao J, Liu Q, Bejna A, Thomas RD, Bandyopadhyay S, Bismar TA, Neill D, **Azoulay L**, Batist G, Kandouz M. Role of the EphB2 receptor in autophagy, apoptosis and invasion in human breast cancer cells. *Exp Cell Res* 2014;320(2):233-46.
14. Yu O*, Eberg M, Benayoun S, Aprikian A, Batist G, Suissa S, **Azoulay L**. Use of statins and the risk of death in patients with prostate cancer. *J Clin Oncol* 2014;32(1):5-11.

Mark Basik

1. Przybytkowski E, Lenkiewicz E, Barrett MT, Klein K, Nabavi S, Greenwood CM, **Basik M**. Chromosome-breakage genomic instability and chromothripsis in breast cancer. *BMC Genomics*. 2014 Jul 9;15:579. doi: 10.1186/1471-2164-15-579.
2. Nelson NC, Keating P, Cambrosio A, Aguilar-Mahecha A, **Basik M**. Testing devices or experimental systems? Cancer clinical trials take the genomic turn. *Soc Sci Med*. 2014 Jun;111:74-83. doi: 10.1016/j.socscimed.2014.04.008. Epub 2014 Apr 12.
3. Henriques L, Palumbo M, Guay MP, Bahoric B, **Basik M**, Kavan P, Batist G. Imiquimod in the treatment of breast cancer skin metastasis. *J Clin Oncol*. 2014 Mar 10;32(8):e22-5. doi: 10.1200/JCO.2012.46.4883. Epub 2014 Jan 13. No abstract available.

Nicole Beauchemin

1. E. Xu, M.-P. Forest, M. Schwab, R. Kohen Avramoglu, E. St-Amand, K. Bellmann, G. Voisin, M. Paquet, A. Montoudis, E. Lévy, K. A. Siminovitch, B. G. Neel, **N. Beauchemin**, and A. Marette. Hepatocyte-specific *Ptpn6* deletion promotes hepatic steatosis, but reduces non-alcoholic fatty liver disease in diet-induced obesity: potential role of PPAR γ . *Hepatology* 59(5):1803-15 (2014). doi: 10.1002/hep.26957.
2. J. Hudson, V. Sabourin, J. Ha, R. Ahn, R. La Selva, J. Livinstone, L. Podmore, J. Knight, L. Forrest, **N. Beauchemin**, M. Hallett, M. Park, and J. Ursini-Siegel. p66ShcA Promotes Breast Cancer Plasticity by Inducing an Epithelial to Mesenchymal Transition. *Mol. Cell Biol.*, 34(19): 3689-701(2014).
3. B. Foveau, L. Van der Kraak, **N. Beauchemin**, J. Ursini-Siegel, S. Albrecht, A. C. LeBlanc. Inflammation-induced tumorigenesis in the colon is not dependent on Caspase-6. *PLoSOne*. 2014 Dec 3;9(12):e114270.

Martin Black

1. Henry M, Ho A, Lambert SD, Carnevale FA, Greenfield B, MacDonald C, Mlynarek A, Zeitouni A, Rosberger Z, Hier M, **Black M**, Kost K, Frenkiel S. Looking beyond disfigurement: the experience of patients with head and neck cancer. *J Palliat Care*. 2014 Spring;30(1):5-15.

Manuel Borod

1. **Borod M.** Clarification of Borod's comments about Bill 52. *CMAJ*. 2014 Jun 10;186(9):697. doi: 10.1503/cmaj.114-0042.
2. Viganò AL, di Tomasso J, Kilgour RD, Trutschnigg B, Lucar E, Morais JA, **Borod M.** The abridged patient-generated subjective global assessment is a useful tool for early detection and characterization of cancer cachexia. *J Acad Nutr Diet*. 2014 Jul;114(7):1088-98. doi: 10.1016/j.jand.2013.09.027. Epub 2014 Jan 24.

Nathanial Bouganim

1. Gurberg J, **Bouganim N**, Shenouda G, Zeitouni A. A case of recurrent anaplastic meningioma of the skull base with radiologic response to hydroxyurea. *J Neurol Surg Rep*. 2014 Aug;75(1):e52-5. doi: 10.1055/s-0033-1359300. Epub 2014 Apr 17.
2. Couraud S, Dell'Aniello S, **Bouganim N**, Azoulay L. Cardiac glycosides and the risk of breast cancer in women with chronic heart failure and supraventricular arrhythmia. *Breast Cancer Res Treat*. 2014 Aug;146(3):619-26. doi: 10.1007/s10549-014-3058-8. Epub 2014 Jul 20.
3. Villarreal-Garza C, Khalaf D, **Bouganim N**, Clemons M, Peña-Curiel O, Baez-Revueltas B, Kiss A, Kassam F, Enright K, Verma S, Pritchard K, Myers J, Dent R. Platinum-based chemotherapy in triple-negative advanced breast cancer. *Breast Cancer Res Treat*. 2014 Aug;146(3):567-72. doi: 10.1007/s10549-014-3033-4. Epub 2014 Jul 8.
4. Addison CL, **Bouganim N**, Hilton J, Vandermeer L, Dent S, Amir E, Hopkins S, Kuchuk I, Segal R, Song X, Gertler S, Mazzaello S, Dranitsaris G, Ooi D, Pond G, Clemons M. A phase II, multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal-related events. *Breast Cancer Res Treat*. 2014 Apr;144(3):615-24. doi: 10.1007/s10549-014-2906-x. Epub 2014 Mar 18.
5. Khalaf D, Hilton JF, Clemons M, Azoulay L, Yin H, Vandermeer L, Dent S, Hopkins S, **Bouganim N**. Investigating the discernible and distinct effects of platinum-based chemotherapy regimens for metastatic triple-negative breast cancer on time to progression. *Oncol Lett*. 2014 Mar;7(3):866-870. Epub 2014 Jan 7.
6. Saleh RR, **Bouganim N**, Hilton J, Arnaout A, Clemons M. Neoadjuvant endocrine treatment for breast cancer: from bedside to bench and back again? *Curr Oncol*. 2014 Feb;21(1):e122-8. doi: 10.3747/co.21.1627.
7. Beusterien K, Grinspan J, Kuchuk I, Mazzaello S, Dent S, Gertler S, **Bouganim N**, Vandermeer L, Clemons M. Use of conjoint analysis to assess breast cancer patient preferences for chemotherapy side effects. *Oncologist*. 2014 Feb;19(2):127-34. doi: 10.1634/theoncologist.2013-0359. Epub 2014 Jan 28.

Philip Branton

1. Gilson, T., C.Y Cheng, W.S. Hur, P. Blanchette and P.E. Branton. **2014.** Analysis of the Cullin Binding Sites of the E4orf6 Proteins of Human Adenovirus E3 Ubiquitin Ligases. *J. Virol*. 88, 3885-3897.
2. Lu, Y., I. Gamache, P. Blanchette, P. Branton, and J. Teodoro. **2014.** Human adenovirus type 5 E4orf4 interacts with the nucleopore component Nup205 to regulate viral gene expression and enhance virus replication. *J. Virol*. 88, 13249-13259.

Pnina Brodt

1. Van den Eynden GG, Bird NC, Dirix LY, Eefsen RL, Gao ZH, Høyer-Hansen G, Illemann M, Majeed AW, Metrakos P, Reynolds AR, Vainer B, van Dam PJ, Van Laere SJ, Vermeulen PB, Vidal-Vanaclocha F, **Brodt P**. Tumor stromal phenotypes define VEGF sensitivity--letter. Liver Metastasis Research Network. Clin Cancer Res. 2014 Oct 1;20(19):5140. doi: 10.1158/1078-0432.CCR-14-0158.

Prosanto Chaudhury

1. Kao LS, Dimick JB, Porter GA; **Evidence-Based Reviews in Surgery Group**. How do administrative data compare with a clinical registry for identifying 30-day postoperative complications? J Am Coll Surg. 2014 Dec;219(6):1187-91. doi: 10.1016/j.jamcollsurg.2014.09.002. Epub 2014 Nov 18.
2. Chaudhury PK, Jeschke MG, Monson JR; **Evidence Based Reviews in Surgery Group**. What is the diagnostic value of C-reactive protein for the prediction and the exclusion of postoperative infectious complication after colorectal surgery? Can J Surg. 2014 Dec;57(6):417-9. PMID: 25421085
3. Jamal MH, Doi SA, Moser AJ, Dumitra S, abou Khalil J, Simoneau E, **Chaudhury P**, Onitilo AA, Metrakos P, Barkun JS. McGill Brisbane Symptom Score for patients with resectable pancreatic head adenocarcinoma. World J Gastroenterol. 2014 Sep 14;20(34):12226-32. doi: 10.3748/wjg.v20.i34.12226.
4. Pawlik TM, Devon KM, Fields CA, Hinshaw DB; **Evidence-Based Reviews in Surgery Group**. What are patients' expectations about the effects of chemotherapy for advanced cancer? J Am Coll Surg. 2014 Sep;219(3):588-90. doi: 10.1016/j.jamcollsurg.2014.06.008.
5. Boily G, Villeneuve JP, Lacoursière L, **Chaudhury P**, Couture F, Ouellet JF, Lapointe R, Goulet S, Gervais N. Comité de l'évolution des pratiques en oncologie Transarterial embolization therapies for the treatment of hepatocellular carcinoma: CEPO review and clinical recommendations. HPB (Oxford). 2015 Jan;17(1):52-65. doi: 10.1111/hpb.12273. Epub 2014
6. Abou Khalil J, Mayo N, Dumitra S, Jamal M, **Chaudhury P**, Metrakos P, Barkun J. Pancreatic fistulae after a pancreatico-duodenectomy: are pancreatico-gastrostomies safer than pancreatico-jejunostomies? An expertise-based trial and propensity-score adjusted analysis. HPB (Oxford). 2014 Dec;16(12):1062-7. doi: 10.1111/hpb.12294. Epub 2014 Jun 19.
7. Henteleff HJ, Parry NG, Burlew CC; **Evidence-Based Reviews in Surgery Group**. What is the comparative efficacy of negative-pressure wound therapy vs alternate temporary abdominal closure techniques in open abdominal wounds? J Am Coll Surg. 2014 Jun;218(6):1251-3. doi: 10.1016/j.jamcollsurg.2014.03.022.
8. Brown CJ, Achkar JP, Bressler BL, Maclean AR, Remzi FH; **Evidence Based Reviews in Surgery Group**. Canadian Association of General Surgeons, the American College of Surgeons, the Canadian Society of Colorectal Surgeons and the American Society of Colorectal Surgeons Evidence Based Reviews in Surgery - colorectal surgery. Dis Colon Rectum. 2014 Feb;57(2):278-81. doi: 10.1097/DCR.000000000000012. Review.

Robin Cohen

1. *Mehta A, *Chan L, **Cohen SR**. Flying blind: Sources of distress for family caregivers of palliative cancer patients managing pain at home. *Journal of Psychosocial Oncology* 2014 Jan; 32(1):94-111. doi: [10.1080/07347332.2013.856057](https://doi.org/10.1080/07347332.2013.856057)
2. *MacKinnon CJ, Smith NG, Henry M, Milman E, Berish M, Körner A, Copeland L, Chochinov HM, **Cohen SR**. Bridging meaning-based theories with emerging trends in bereavement intervention research: Meaning-based group counseling for bereavement. *Death Studies* 2014; 38(3):137-144.
3. *Shahidi J, Taghizadeh-Kermani A, Gohari MR, Ghavamnasiri MR, Khoshroo F, Pourali L, **Cohen SR**. Changes in daily activities of cancer patients after diagnosis: How do Canadian and Iranian patients perceive the change? *Iranian Journal of Cancer Prevention*. 2014; 7(1):28-34.
4. *Allen D, Badro V, Denyer Willis L, Macdonald ME, Paré A, Hutchinson T, Barré P, Beauchemin R, Bocti H, Broadbent A, **Cohen SR**. Fragmented care and whole-person illness: Decision-making for people with chronic, end-stage kidney disease. *Chronic Illness* 2014; 0(0):1-12. doi: [10.1177/1742395314562974](https://doi.org/10.1177/1742395314562974)
5. **Cohen SR**. (2014). McGill Quality of Life Questionnaire. In: Michalos AC (Ed.). *Encyclopedia of Quality of Life and Well-Being Research*. Springer, Dordrecht, Netherlands: Springer, pp 3883-3889.

Victor Cohen

1. Peter M Ellis, Frances A Shepherd, Michael Millward, Francesco Perrone, Lesley Seymour, Geoffrey Liu, Sophie Sun, Byoung Chul Cho, MD, Alessandro Morabito, MD, Natasha B Leighl, Martin R Stockler, Christopher W Lee, Rafal Wierzbicki, **Victor Cohen**, Normand Blais, Randeep S Sangha, Adolfo G Favaretto, Jin Hyoung Kang, Prof Ming-Sound Tsao, Carolyn F Wilson, Zelanna Goldberg, Keyue Ding, Glenwood D Goss, Penelope Ann Bradbury, on behalf of the NCIC CTG, Australasian Lung Cancer Trials Group, the NCI Naples Clinical Trials Unit (2014). Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial. *The Lancet Oncology*, Volume 15, No. 12, p1379–1388.
2. Esfahani K, Agulnik JS, **Cohen V**. A Systemic Review of Resistance Mechanisms and Ongoing Clinical Trials in ALK-Rearranged Non-Small Cell Lung Cancer. *Front Oncol*. 2014 Jul 21;4:174. doi: [10.3389/fonc.2014.00174](https://doi.org/10.3389/fonc.2014.00174). eCollection 2014. Review.
3. Albanna AS, Kasymjanova G, Robitaille C, **Cohen V**, Brandao G, Pepe C, Small D, Agulnik J. Comparison of the yield of different diagnostic procedures for cellular differentiation and genetic profiling of non-small-cell lung cancer. *J Thorac Oncol*. 2014 Aug;9(8):1120-5. doi: [10.1097/JTO.0000000000000230](https://doi.org/10.1097/JTO.0000000000000230).
4. Ky B, Putt M, Sawaya H, French B, Januzzi JL Jr, Sebag IA, Plana JC, **Cohen V**, Banchs J, Carver JR, Wiegers SE, Martin RP, Picard MH, Gerszten RE, Halpern EF, Passeri J, Kuter I, Scherrer-Crosbie M. Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab. *J Am Coll Cardiol*. 2014 Mar 4;63(8):809-16. doi: [10.1016/j.jacc.2013.10.061](https://doi.org/10.1016/j.jacc.2013.10.061). Epub 2013 Nov 27

Fabio Cury

1. Rodrigues G, Lukka H, Warde P, Brundage M, Souhami L, Crook J, **Cury F**, Catton C, Mok G, Martin AG, Vigneault E, Morris J, Warner A, Maldonado SG, Pickles T; The prostate cancer risk stratification project: database construction and risk stratification outcome analysis. Genitourinary Radiation Oncologists of Canada. *J Natl Compr Canc Netw*. 2014 Jan;12(1):60-9.
2. Turgeon GA, Souhami L, **Cury FL**, Faria SL, Duclos M, Sturgeon J, Kassouf W. Hypofractionated intensity modulated radiation therapy in combined modality treatment for bladder preservation in elderly patients with invasive bladder cancer. *Int J Radiat Oncol Biol Phys*. 2014 Feb 1;88(2):326-31.
3. Dragomir A, Dinea D, Vanhuysse M, **Cury FL**, Aprikian AG. Drug costs in the management of metastatic castration-resistant prostate cancer in Canada. *BMC Health Serv Res*. 2014 Jun 13;14:252.
4. Dragomir A, **Cury FL**, Aprikian AG. Active surveillance for low-risk prostate cancer compared with immediate treatment: a Canadian cost comparison. *CMAJ Open*. 2014 Apr 24;2(2):E60-8.
5. Patel N, Souhami L, Mansure JJ, Duclos M, Aprikian A, Faria S, David M, **Cury FL**. PSA Bounce after HDR Prostate Brachytherapy and Hypofractionated External Beam Radiotherapy. *Brachytherapy*. 2014 Sep-Oct;13(5):450-5.
6. Sanyal C, Aprikian A, **Cury F**, Chevalier S, Dragomir A. Clinical management and burden of prostate cancer: a markov monte carlo model. *PLoS One*. 2014 Dec 4;9(12):e113432.

Marc David

1. Patel N, Souhami L, Mansure JJ, Duclos M, Aprikian A, Faria S, **David M**, Cury FL. Prostate-specific antigen bounce after high-dose-rate prostate brachytherapy and hypofractionated external beam radiotherapy. *Brachytherapy*. 2014 Sep-Oct;13(5):450-5. doi: 10.1016/j.brachy.2014.05.005. Epub 2014 Jul 10.
2. Madani A, Spicer J, Alcindor T, **David M**, Vanhuysse M, Asselah J, Mulder D, Ferri L. Clinical significance of incidental pulmonary nodules in esophageal cancer patients. *J Gastrointest Surg*. 2014 Feb;18(2):226-32; discussion 232-3. doi: 10.1007/s11605-013-2339-6. Epub 2013 Sep 4.

Slobodan Devic

1. Mujica-Mota MA, Salehi P, **Devic S**, Daniel SJ, "Safety and Otoprotection of Metformin in Radiation-Induced Sensorineural Hearing Loss in the Guinea Pig," *Otolaryngol Head Neck Surg*. 2014 May; 150(5): 859-65. doi: 10.1177/0194599814521013
2. Mario A. Mujica-Mota, Shirley Lehnert, **Slobodan Devic**, Karina Gasbarrino, Sam J. Daniel, "Mechanisms of radiation-induced sensorineural hearing loss and radioprotection," *Hearing Research* 312 (2014) 60-68.
3. Mario A. Mujica-Mota, **Slobodan Devic**, and Sam J. Daniel, "The Relevance of Dosimetry in Animal Models of Cochlear Irradiation," *Otology & Neurotology* 35, 704-711 (2014).
4. Dae Yup Han, Matthew J. Webster, Daniel J. Scanderbeg, Catheryn Yashar, Dongju Choi, Bongyong Song, **Slobodan Devic**, Ananth Ravi, William Y. Song, "Direction-Modulated Brachytherapy for High-Dose-Rate Treatment of Cervical Cancer. I: Theoretical Design," *Intl. J. Radiat. Oncol. Biol. Phys.* 89(3), 666-673 (2014). (<http://dx.doi.org/10.1016/j.ijrobp.2014.02.039>)

5. Mujica-Mota, MA; Ibrahim, FF; Bezdjian, A; Devic, S; Daniel, SJ; "The Effect of Fractionated Radiotherapy in Sensorineural Hearing Loss: An Animal Model," *Laryngoscope* 124, E418-E424 (2014).
6. Ahmad Nobah, Saad Aldelajjan, Slobodan Devic, Nada Tomic, Jan Seuntjens, Mohammed Al-Shabanah, Belal Moftah, "Radiochromic Film Based Dosimetry of Image Guidance Procedures on Different Radiotherapy Modalities," *J. Appl. Clin. Med. Phys.* 15(6), 229-239 (2014).

Marie Duclos

1. Patel N, Souhami L, Mansure JJ, **Duclos M**, Aprikian A, Faria S, David M, Cury FL. Prostate-specific antigen bounce after high-dose-rate prostate brachytherapy and hypofractionated external beam radiotherapy. *Brachytherapy*. 2014 Sep-Oct;13(5):450-5. doi: 10.1016/j.brachy.2014.05.005. Epub 2014 Jul 10.
2. Turgeon GA, Souhami L, Cury FL, Faria SL, **Duclos M**, Sturgeon J, Kassouf W. Hypofractionated intensity modulated radiation therapy in combined modality treatment for bladder preservation in elderly patients with invasive bladder cancer. *Int J Radiat Oncol Biol Phys*. 2014 Feb 1;88(2):326-31. doi: 10.1016/j.ijrobp.2013.11.005.

Nicoletta Eliopoulos

1. Cuerquis J, Romieu-Mourez R, François M, Routy JP, Young YK, Zhao J, **Eliopoulos N**. Human mesenchymal stromal cells transiently increase cytokine production by activated T cells before suppressing T-cell proliferation: effect of interferon- γ and tumor necrosis factor- α stimulation. *Cytotherapy*. 2014 Feb;16(2):191-202. doi: 10.1016/j.jcyt.2013.11.008.

Issam El Naqa

1. **El Naqa I**, "The role of quantitative PET in predicting cancer treatment outcomes," Special issue on Trends in PET Quantification, Clinical and Translational Imaging, May, 2014.
2. **El Naqa I**, "Biomedical informatics and panomics for evidence-based radiation therapy," *WIRES: Data Mining and Knowledge Discovery*, Advanced Review. July, 2014.
3. *James Coates, Norma Ybarra, Issam El Naqa, "Novel Non-Invasive Plethysmograph for Robust Assessment and Prediction of Radiation-Induced Lung Injury," *Physiological Measurement*, 35, 1737-, 2014 (Featured article).
4. *Piotr Pater, Mario A Bernal, Jan P Seuntjens, **Issam El Naqa**, "On the Consistency of Monte Carlo Track Structure DNA Damage Simulations," *Medical Physics*, Vol. 41, no. 12, 2014.
5. Mathieu Hatt, Mohamed Majdoub, Martin Vallières, Florent Tixier, David Groheux, Marc Espié, Antoine Martineau, Olivier Pradier, Roland Hustinx, Catherine Cheze Le Rest, **Issam El Naqa**, Dimitris Visvikis, "FDG PET uptake characterization through texture analysis: investigating the complementary nature of heterogeneity and functional tumor volume in a multicancer model patient cohort," *J Nucl Med*. 2014 Dec 11. pii: jnumed.114.144055. [Epub ahead of print].
6. Maria OM, Maria AM, Ybarra N, Jeyaseelan K, Lee S, Perez J, Shalaby MY, Lehnert S, Faria S, Serban M, Seuntjens J, **El Naqa I**. Mesenchymal Stem Cells Adopt Lung Cell Phenotype in Normal and Radiation- Induced Lung Injury Conditions. (*Applied Immunohistochemistry & Molecular Morphology*), accepted, 2014.

7. **El Naqa I.**, “The Role of Big Data in Radiation Oncology: Challenges and Potentials,” Big Data Analytics in Bioinformatics and Healthcare. Editor (Elizabeth Wang), IGI Global, Hershey, 2014

Shirin Enger

1. Quentin E. Adams, Jinghzu Xu, Elizabeth K. Breitbach, Xing Li, **Shirin A. Enger**, William R. Rockey, Yusung Kim, Xiaodong Wu, and Ryan T. Flynn. Interstitial rotating shield brachytherapy for prostate cancer. *Medical Physics* 41, 051703 (2014); doi: 10.1118/1.4870441

Michael Evans

1. M. Evans, C. Hudon, E.B. Podgorsak, C.R. Freeman; **Institutional experience with a rotational total skin electron irradiation (RTSEI) technique – A three decade review (1981 – 2012).**: Reports of Practical Oncology and Radiotherapy, Vol 19, pp 120 – 134, 2014.

Marc Fabian

1. Rouya C, Siddiqui N, Morita M, Duchaine TF, **Fabian MR** (co-corresponding author), Sonenberg N. Human DDX6 effects miRNA-mediated gene silencing via direct binding to CNOT1. *RNA*. 2014 Sep;20(9):1398-409. doi: 10.1261/rna.045302.114. Epub 2014 Jul 17.

Sergio Faria

1. **Faria S**, Kopek N, Hijal T, Liberman S, Charlebois P, Stein B, Meterissian S, Meguerditchian A, Fawaz Z, Artho G. Phase II trial of short-course radiotherapy followed by delayed surgery for locoregionally advanced rectal cancer. *Colorectal Dis*. 2014 Feb;16(2):O66-70.
2. Cheung P, **Faria S**, Ahmed S, Chabot P, Greenland J, Kurien E, Mohamed I, Wright JR, Hollenhorst H, de Metz C, Campbell H, Vu TT, Karvat A, Wai ES, Ung YC, Goss G, Shepherd FA, O'Brien P, Ding K, O'Callaghan C. Phase II study of accelerated hypofractionated three-dimensional conformal radiotherapy for stage T1-3 N0 M0 non-small cell lung cancer: NCIC CTG BR.25. *J Natl Cancer Inst*. 2014 Jul 29;106(8). Print 2014 Aug.

Cristiano Ferrario

1. Esfahani K, **Ferrario C**, Le P, Panasci L. Aromatase inhibition in relapsing low malignant potential serous tumours of the ovary. *BMJ Case Rep*. 2014 Jun 12;2014. pii: bcr2014204287. doi: 10.1136/bcr-2014-204287.
2. Ferrario C, Batist G. Advances in the approach to novel drug clinical development for breast cancer. *Expert Opin Drug Discov*. 2014 Jun;9(6):647-68. doi: 10.1517/17460441.2014.911282. Epub 2014 Apr 23. Review.

William Foulkes

1. Lefebvre M, **Foulkes WD**. Pheochromocytoma and paraganglioma syndromes: genetics and management update. *Curr Oncol*. 2014 Feb;21(1):e8-e17. doi: 10.3747/co.21.1579.

2. Metcalfe K, Gershman S, Ghadirian P, Lynch HT, Snyder C, Tung N, Kim-Sing C, Eisen A, **Foulkes WD**, Rosen B, Sun P, Narod SA. Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis. *BMJ*. 2014 Feb 11;348:g226. doi: 10.1136/bmj.g226.
3. Murray MJ, Bailey S, Raby KL, Saini HK, de Kock L, Burke GA, **Foulkes WD**, Enright AJ, Coleman N, Tischkowitz M. Serum levels of mature microRNAs in DICER1-mutated pleuropulmonary blastoma. *Oncogenesis*. 2014 Feb 10;3:e87. doi: 10.1038/oncsis.2014.1.
4. Witkowski L, Carrot-Zhang J, Albrecht S, Fahiminiya S, Hamel N, Tomiak E, Grynspan D, Saloustros E, Nadaf J, Rivera B, Gilpin C, Castellsagué E, Silva-Smith R, Plourde F, Wu M, Saskin A, Arseneault M, Karabakhtsian RG, Reilly EA, Ueland FR, Margiolaki A, Pavlakis K, Castellino SM, Lamovec J, Mackay HJ, Roth LM, Ulbright TM, Bender TA, Georgoulis V, Longy M, Berchuck A, Tischkowitz M, Nagel I, Siebert R, Stewart CJ, Arseneau J, McCluggage WG, Clarke BA, Riazalhosseini Y, Hasselblatt M, Majewski J, **Foulkes WD**. Germline and somatic *SMARCA4* mutations characterize small cell carcinoma of the ovary, hypercalcaemic type. *Nature Genetics*, 2014 May;46(5):438-43
5. Narod SA, Tung N, Lubinski J, Huzarski T, Robson M, Lynch HT, Neuhausen SL, Ghadirian P, Kim-Sing C, Sun P, **Foulkes WD**; Hereditary Breast Cancer Clinical Study Group. A prior diagnosis of breast cancer is a risk factor for breast cancer in BRCA1 and BRCA2 carriers. *Curr Oncol*. 2014 Apr;21(2):64-8. doi: 10.3747/co.21.1656.
6. Gavino C, Cotter A, Lichtenstein D, Lejtenyi D, Fortin C, Legault C, Alirezaie N, Majewski J, Sheppard DC, Behr MA, **Foulkes WD**, Vinh DC. CARD9 deficiency and spontaneous central nervous system candidiasis: complete clinical remission with GM-CSF therapy. *Clin Infect Dis*. 2014 Apr 4. [Epub ahead of print
7. Navarro de Souza A, Groleau D, Loiselle CG, **Foulkes WD**, Wong N. Cultural Aspects of Healthy BRCA Carriers From Two Ethnocultural Groups. *Qual Health Res*. 2014 May;24(5):665-81. doi: 10.1177/1049732314528756. Epub 2014 Apr 1.
8. de Kock L, Sabbaghian N, Soglio DB, Guillerman RP, Park BK, Chami R, Deal CL, Priest JR, **Foulkes WD**. Exploring the association between DICER1 mutations and differentiated thyroid carcinoma. *J Clin Endocrinol Metab*. 2014 Jun;99(6):E1072-7. doi: 10.1210/jc.2013-4206.
9. Finch AP, Lubinski J, Møller P, Singer CF, Karlan B, Senter L, Rosen B, Maehle L, Ghadirian P, Cybulski C, Huzarski T, Eisen A, **Foulkes WD**, Kim-Sing C, Ainsworth P, Tung N, Lynch HT, Neuhausen S, Metcalfe KA, Thompson I, Murphy J, Sun P, Narod SA. Impact of Oophorectomy on Cancer Incidence and Mortality in Women with a BRCA1 or BRCA2 Mutation. *J Clin Oncol*. 2014 Feb 24. [Epub ahead of print] PubMed PMID: 24567435
10. Rath SR, Bartley A, Charles A, Powers N, Baynam G, Priest JR, **Foulkes WD**, Choong CSY. Multinodular Goiter in Children: an Important Pointer to a Germline DICER1 Mutation. *J Clin Endocrinol Metab*, 2014 Jun;99(6):1947-8. PMID: 24628552
11. **Foulkes WD**, Clarke BA, Hasselblatt M, Majewski J, Albrecht S, McCluggage WG. TEST No small surprise - small cell carcinoma of the ovary, hypercalcaemic type, is a malignant rhabdoid tumour. *J Pathol*. 2014 Jul;233(3):209-14. doi: 10.1002/path.4362. Epub 2014 May 20. PMID: 24752781

12. de Kock L, Sabbaghian N, Plourde F, Srivastava A, Weber E, Bouron-Dal Soglio D, Hamel N, Choi JH, Park SH, Deal CL, Kelsey MM, Dishop MK, Esbenshade A, Kuttesch JF, Jacques TS, Perry A, Leichter H, Maeder P, Brundler MA, Warner J, Neal J, Zacharin M, Korbonits M, Cole T, Traunecker H, McLean TW, Rotondo F, Lepage P, Albrecht S, Horvath E, Kovacs K, Priest JR, **Foulkes WD**. Pituitary blastoma: a pathognomonic feature of germ-line DICER1 mutations. *Acta Neuropathol*. 2014 Jul;128(1):111-22. doi: 10.1007/s00401-014-1285-z. Epub 2014 May 20. PMID: 24839956
13. **Foulkes WD**. Made-to-measure medicine: BRCA and gynaecological cancer. *Lancet Oncol*. 2014 Jul;15(8):783-5. doi: 10.1016/S1470-2045(14)70246-3. Epub 2014 May 31. PMID: 24882435
14. Gronwald J, Robidoux A, Kim-Sing C, Tung N, Lynch HT, **Foulkes WD**, Manoukian S, Ainsworth P, Neuhausen SL, Demsky R, Eisen A, Singer CF, Saal H, Senter L, Eng C, Weitzel J, Moller P, Gilchrist DM, Olopade O, Ginsburg O, Sun P, Huzarski T, Lubinski J, Narod SA. Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Hereditary Breast Cancer Clinical Study Group. *Breast Cancer Res Treat*. 2014 Jul;146(2):421-7. doi: 10.1007/s10549-014-3026-3. Epub 2014 Jun 21. PMID: 24951267
15. Schrader KA, Stratton KL, Murali R, Laitman Y, Cavallone L, Offit L, Wen YH, Thomas T, Shah S, Rau-Murthy R, Manschreck C, Salo-Mullen E, Otegbeye E, Corines M, Zhang L, Norton L, Hudis C, Klein RJ, Kauff ND, Robson M, Stadler ZK, Haber DA, Lipkin SM, Friedman E, **Foulkes WD**, Altshuler D, Vijai J, Offit K. Genome Sequencing of Multiple Primary Tumors Reveals a Novel PALB2 Variant. *J Clin Oncol*. 2014 Jun 30. pii: JCO.2013.50.0272. PMID: 24982446
16. Giannakeas V, Lubinski J, Gronwald J, Moller P, Armel S, Lynch HT, **Foulkes WD**, Kim-Sing C, Singer C, Neuhausen SL, Friedman E, Tung N, Senter L, Sun P, Narod SA. Mammography screening and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a prospective study. *Breast Cancer Res Treat*. 2014 Aug;147(1):113-8. doi: 10.1007/s10549-014-3063-y. Epub 2014 Aug 1. PMID: 25082516
17. Antoniou AC, Casadei S, Heikkinen T, Barrowdale D, Pylkäs K, Roberts J, Lee A, Subramanian D, De Leeneer K, Fostira F, Tomiak E, Neuhausen SL, Teo ZL, Khan S, Aittomäki K, Moilanen JS, Turnbull C, Seal S, Mannermaa A, Kallioniemi A, Lindeman GJ, Buys SS, Andrulis IL, Radice P, Tondini C, Manoukian S, Toland AE, Miron P, Weitzel JN, Domchek SM, Poppe B, Claes KB, Yannoukacos D, Concannon P, Bernstein JL, James PA, Easton DF, Goldgar DE, Hopper JL, Rahman N, Peterlongo P, Nevanlinna H, King MC, Couch FJ, Southey MC, Winqvist R, **Foulkes WD**, Tischkowitz M. Breast-cancer risk in families with mutations in PALB2. *N Engl J Med*. 2014 Aug 7;371(6):497-506. doi: 10.1056/NEJMoa1400382. PMID: 25099575
18. Hartley T, Cavallone L, Sabbaghian N, Silva-Smith R, Hamel N, Aleynikova O, Smith E, Hastings V, Pinto P, Tischkowitz M, Tomiak E, **Foulkes WD**. Mutation analysis of PALB2 in BRCA1 and BRCA2-negative breast and/or ovarian cancer families from Eastern Ontario, Canada. *Hered Cancer Clin Pract*. 2014 Aug 28;12(1):19. doi: 10.1186/1897-4287-12-19. eCollection 2014. PMID: 25225577.

19. Bancroft EK, Page EC, Castro E, Lilja H, Vickers A, Sjoberg D, Assel M, Foster CS, Mitchell G, Drew K, Mæhle L, Axcrona K, Evans DG, Bulman B, Eccles D, McBride D, van Asperen C, Vasen H, Kiemeny LA, Ringelberg J, Cybulski C, Wokolorczyk D, Selkirk C, Hulick PJ, Bojesen A, Skytte AB, Lam J, Taylor L, Oldenburg R, Cremers R, Verhaegh G, van Zelst-Stams WA, Oosterwijk JC, Blanco I, Salinas M, Cook J, Rosario DJ, Buys S, Conner T, Ausems MG, Ong KR, Hoffman J, Domchek S, Powers J, Teixeira MR, Maia S, **Foulkes WD**, Taherian N, Ruijs M, Helderman-van den Enden AT, Izatt L, Davidson R, Adank MA, Walker L, Schmutzler R, Tucker K, Kirk J, Hodgson S, Harris M, Douglas F, Lindeman GJ, Zgajnar J, Tischkowitz M, Clowes VE, Susman R, Ramón y Cajal T, Patcher N, Gadea N, Spigelman A, van Os T, Liljegren A, Side L, Brewer C, Brady AF, Donaldson A, Stefansdottir V, Friedman E, Chen-Shtoyerman R, Amor DJ, Copakova L, Barwell J, Giri VN, Murthy V, Nicolai N, Teo SH, Greenhalgh L, Strom S, Henderson A, McGrath J, Gallagher D, Aaronson N, Ardern-Jones A, Bangma C, Dearnaley D, Costello P, Eyfjord J, Rothwell J, Falconer A, Gronberg H, Hamdy FC, Johannsson O, Khoo V, Kote-Jarai Z, Lubinski J, Axcrona U, Melia J, McKinley J, Mitra AV, Moynihan C, Rennert G, Suri M, Wilson P, Killick E; IMPACT Collaborators, Moss S, Eeles RA. Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study. *Eur Urol.* 2014 Sep;66(3):489-99. doi: 10.1016/j.eururo.2014.01.003. Epub 2014 Jan 15. PMID: 24484606.
20. Chui MH, Ryan P, Radigan J, Ferguson SE, Pollett A, Aronson M, Semotiuk K, Sy K, Kwon JS, Soma A, Singh N, Gallinger S, Shaw P, Arseneau J, **Foulkes WD**, Gilks CB, Clarke BA. The Histomorphology of Lynch Syndrome-associated Ovarian Carcinomas: Toward a Subtype-specific Screening Strategy. *Am J Surg Pathol.* 2014 Sep;38(9):1173-81. doi: 10.1097/PAS.0000000000000298. PMID: 25025451
21. Hasselblatt M, Nagel I, Oyen F, Bartelheim K, Russell RB, Schüller U, Junckerstorff R, Rosenblum M, Alassiri AH, Rossi S, Schmid I, Gottardo NG, Toledano H, Viscardi E, Balbin M, Witkowski L, Lu Q, Betts MJ, **Foulkes WD**, Siebert R, Frühwald MC, Schneppenheim R. SMARCA4-mutated atypical teratoid/rhabdoid tumors are associated with inherited germline alterations and poor prognosis. *Acta Neuropathol.* 2014 Sep;128(3):453-6. doi: 10.1007/s00401-014-1323-x. Epub 2014 Jul 25. PMID: 25060813.
22. Liu S, **Foulkes WD**, Leung S, Gao D, Lau S, Kos Z, Nielsen TO. Prognostic significance of FOXP3+ tumor infiltrating lymphocytes in breast cancer depends on estrogen receptor and human epidermal growth factor receptor-2 expression status and concurrent cytotoxic T-cell infiltration. *Breast Cancer Res.* 2014 Sep;16(5):432. [Epub ahead of print] PMID: 25193543.
23. **Foulkes WD**, Priest JR, Duchaine TF. DICER1: mutations, microRNAs and mechanisms. *Nat Rev Cancer.* 2014 Oct;14(10):662-72. doi: 10.1038/nrc3802. Epub 2014 Sept 1. Review. PMID: 25176334.
24. **Foulkes WD**. Screening mammography: the turning of the tide? *Curr Oncol.* 2014 Oct;21(5):205-7. doi: 10.3747/co.21.2253. PMID: 25302028.
25. de Kock L, Sabbaghian N, Druker H, Weber E, Hamel N, Miller S, Choong CS, Gottardo NG, Kees UR, Rednam SP, van Hest LP, Jongmans MC, Jhangiani S, Lupski JR, Zacharin M, Bouron-Dal Soglio D, Huang A, Priest JR, Perry A, Mueller S, Albrecht S, Malkin D, Grundy RG, **Foulkes WD**. Germ-line and somatic DICER1 mutations in pineoblastoma. *Acta Neuropathol.* 2014 Oct;128(4):583-95. doi: 10.1007/s00401-014-1318-7. Epub 2014 Jul 15. PMID: 25022261.

26. Bailey S, Murray MJ, Witkowski L, Hook E, Hasselblatt M, Crawford R, **Foulkes WD**, Tischkowitz M, Nicholson JC. Biallelic somatic SMARCA4 mutations in small cell carcinoma of the ovary, hypercalcemic type (SCCOHT). *Pediatr Blood Cancer*. 2014 Oct 12. doi: 10.1002/pbc.25279. [Epub ahead of print] PMID: 25307865.
27. Castellsagué E, Liu J, Volenik A, Giroux S, Gagné R, Maranda B, Roussel-Jobin A, Latreille J, Laframboise R, Palma L, Kasprzak L, Marcus VA, Breguet M, Nolet S, El-Haffaf Z, Australie K, Gologan A, Aleynikova O, Oros-Klein K, Greenwood C, Mes-Masson AM, Provencher D, Tischkowitz M, Chong G, Rousseau F, **Foulkes WD**. Characterization of a novel founder MSH6 mutation causing Lynch syndrome in the French Canadian population. *Clin Genet*. 2014 Oct 16. doi: 10.1111/cge.12526. [Epub ahead of print] PMID: 25318681
28. A practical guide to human cancer genetics; fourth edition: Hodgson SV, Foulkes WD, Eng C and Maher ER. Springer Verlag, 2014

Eduardo Franco

1. Spence AR, Alobaid A, Drouin P, Goggin P, Gilbert L, Provencher D, Tousignant P, Hanley JA, **Franco EL**. Screening histories and contact with physicians as determinants of cervical cancer risk in Montreal, Quebec. *Curr Oncol*. 2014 Dec;21(6):294-304. doi: 10.3747/co.21.2056.
2. Dahlstrom KR, Burchell AN, Ramanakumar AV, Rodrigues A, Tellier PP, Hanley J, Coutlée F, **Franco EL**. Sexual transmission of oral human papillomavirus infection among men. *Cancer Epidemiol Biomarkers Prev*. 2014 Dec;23(12):2959-64. doi: 10.1158/1055-9965.EPI-14-0386. Epub 2014 Nov 12.
3. Smith LW, Khurshed F, van Niekerk DJ, Krajden M, Greene SB, Hobbs S, Coldman AJ, **Franco EL**, Ogilvie GS. Women's intentions to self-collect samples for human papillomavirus testing in an organized cervical cancer screening program. *BMC Public Health*. 2014 Oct 10;14:1060. doi: 10.1186/1471-2458-14-1060.
4. Tota JE, Ramanakumar AV, Villa LL, Richardson H, Burchell AN, Koushik A, Mayrand MH, Coutlée F, **Franco EL**. Evaluation of human papillomavirus type replacement postvaccination must account for diagnostic artifacts: masking of HPV52 by HPV16 in anogenital specimens. *Cancer Epidemiol Biomarkers Prev*. 2015 Jan;24(1):286-90. doi: 10.1158/1055-9965.EPI-14-0566. Epub 2014 Oct 2.
5. Isidean SD, Tota JE, Gagnon JA, **Franco EL**. Human papillomavirus vaccines: key factors in planning cost-effective vaccination programs. *Expert Rev Vaccines*. 2015 Jan;14(1):119-33. doi: 10.1586/14760584.2015.964213. Epub 2014 Sep 30.
6. Louvanto K, **Franco EL**, Ramanakumar AV, Vasiljević N, Scibior-Bentkowska D, Koushik A, Cuzick J, Coutlée F, Lorincz AT; Biomarkers of Cervical Cancer Risk Study Team. Methylation of viral and host genes and severity of cervical lesions associated with human papillomavirus type 16. *Int J Cancer*. 2015 Mar 15;136(6):E638-45. doi: 10.1002/ijc.29196. Epub 2014 Sep 19.
7. Laprise JF, Drolet M, Boily MC, Jit M, Sauvageau C, **Franco EL**, Lemieux-Mellouki P, Malagón T, Brisson M. Comparing the cost-effectiveness of two- and three-dose schedules of human papillomavirus vaccination: a transmission-dynamic modelling study. *Vaccine*. 2014 Oct 7;32(44):5845-53. doi: 10.1016/j.vaccine.2014.07.099. Epub 2014 Aug 12.

8. **Franco EL**, Shinder GA, Tota JE, Isidean SD. Striving for excellence while adapting to change: redefining our mission of serving the preventive medicine community. *Prev Med.* 2014 Oct;67:311-2. doi: 10.1016/j.ypmed.2014.07.021. Epub 2014 Jul 21. No abstract available.
9. Tota JE, Ramana-Kumar AV, El-Khatib Z, **Franco EL**. The road ahead for cervical cancer prevention and control. *Curr Oncol.* 2014 Apr;21(2):e255-64. doi: 10.3747/co.21.1720.
10. Jelen MM, Chen Z, Kocjan BJ, Burt FJ, Chan PK, Chouhy D, Combrinck CE, Coutlée F, Estrade C, Ferenczy A, Fiander A, **Franco EL**, Garland SM, Giri AA, González JV, Gröning A, Heidrich K, Hibbitts S, Hošnjak L, Luk TN, Marinic K, Matsukura T, Neumann A, Oštrbenk A, Picconi MA, Richardson H, Sagadin M, Sahli R, Seedat RY, Seme K, Severini A, Sinchi JL, Smahelova J, Tabrizi SN, Tachezy R, Tohme S, Uloza V, Vitkauskiene A, Wong YW, Zidovec Lepej S, Burk RD, Poljak M. Global genomic diversity of human papillomavirus 6 based on 724 isolates and 190 complete genome sequences. *J Virol.* 2014 Jul;88(13):7307-16. doi: 10.1128/JVI.00621-14. Epub 2014 Apr 16.
11. Burchell AN, Rodrigues A, Moravan V, Tellier PP, Hanley J, Coutlée F, **Franco EL**. Determinants of prevalent human papillomavirus in recently formed heterosexual partnerships: a dyadic-level analysis. *J Infect Dis.* 2014 Sep 15;210(6):846-52. doi: 10.1093/infdis/jiu200. Epub 2014 Mar 27.
12. Santos F, Dragomir A, Kassouf W, **Franco EL**, Aprikian A. Predictors of preoperative delays before radical cystectomy for bladder cancer in Quebec, Canada: a population-based study. *BJU Int.* 2015 Mar;115(3):389-96. doi: 10.1111/bju.12742. Epub 2014 Jul 27.
13. Smith MA, Tellier PP, Roger M, Coutlée F, **Franco EL**, Richardson H. Determinants of human papillomavirus coinfections among Montreal university students: the influence of behavioral and biologic factors. *Cancer Epidemiol Biomarkers Prev.* 2014 May;23(5):812-22. doi: 10.1158/1055-9965.EPI-13-1255. Epub 2014 Feb 25.
14. Dal-Ré R, Ioannidis JP, Bracken MB, Buffler PA, Chan AW, **Franco EL**, La Vecchia C, Weiderpass E. Making prospective registration of observational research a reality. *Sci Transl Med.* 2014 Feb 19;6(224):224cm1. doi: 10.1126/scitranslmed.3007513.
15. Louvanto K, Chevarie-Davis M, Ramanakumar AV, **Franco EL**, Ferenczy A. HPV testing with cytology triage for cervical cancer screening in routine practice. *Am J Obstet Gynecol.* 2014 May;210(5):474.e1-7. doi: 10.1016/j.ajog.2013.12.033. Epub 2013 Dec 25.
16. de Araujo-Souza PS, Ramanakumar AV, Candeias JM, Thomann P, Trevisan A, **Franco EL**, Villa LL; Ludwig-McGill Cohort Study. Determinants of baseline seroreactivity to human papillomavirus type 16 in the Ludwig-McGill cohort study. *BMC Infect Dis.* 2014 Nov 18;14:578. doi: 10.1186/s12879-014-0578-0.
17. Isidean SD, Coutlée F, Franco EL. cobas 4800 HPV Test, a real-time polymerase chain reaction assay for the detection of human papillomavirus in cervical specimens. *Expert Rev Mol Diagn.* 2014 Jan;14(1):5-16. doi: 10.1586/14737159.2014.865521. Epub 2013 Dec 2.
18. Isidean SD, **Franco EL**. Embracing a new era in cervical cancer screening. *Lancet.* 2014 Feb 8;383(9916):493-4. doi: 10.1016/S0140-6736(13)62028-0. Epub 2013 Nov 3. No abstract available.
19. Drolet M, Laprise JF, Boily MC, **Franco EL**, Brisson M. Potential cost-effectiveness of the nonavalent human papillomavirus (HPV) vaccine. *Int J Cancer.* 2014 May 1;134(9):2264-8. doi: 10.1002/ijc.28541. Epub 2013 Oct 31.

20. Tota JE, Ramanakumar AV, **Franco EL**. Lung cancer screening: review and performance comparison under different risk scenarios. *Lung*. 2014 Feb;192(1):55-63. doi: 10.1007/s00408-013-9517-x. Epub 2013 Oct 24. Review.

Carolyn Freeman

1. Evans MDC, Hudon C, Podgorsak E, **Freeman C**. Institutional experience with a rotational total skin electron irradiation technique - a three-decade review (1981-2012). *Reports of Practical Oncology and Radiotherapy* 2014;19:120-134
2. Sarfehnia A, Davis S, Poon E, Fleming A, Mitchell D, **Freeman C**. A novel approach to total skin irradiation using helical tomotherapy. *Practical Radiation Oncology* 2014; 4:330-335

Vincent Giguere

1. Audet-Walsh É, **Giguère V**. The multiple universes of estrogen-related receptor α and γ in metabolic control and related diseases. *Acta Pharmacol Sin*. 2015 Jan;36(1):51-61. doi: 10.1038/aps.2014.121. Epub 2014 Dec 15.
2. Liu X, **Giguère V**. Inactivation of RAR β inhibits Wnt1-induced mammary tumorigenesis by suppressing epithelial-mesenchymal transitions. *Nucl Recept Signal*. 2014 Nov 4;12:e004. doi: 10.1621/nrs.12004. eCollection 2014.
3. Perry MC, Dufour CR, Tam IS, B'chir W, **Giguère V**. Estrogen-related receptor- α coordinates transcriptional programs essential for exercise tolerance and muscle fitness. *Mol Endocrinol*. 2014 Dec;28(12):2060-71. doi: 10.1210/me.2014-1281.
4. Sailland J, Tribollet V, Forcet C, Billon C, Barenton B, Carnesecchi J, Bachmann A, Gauthier KC, Yu S, **Giguère V**, Chan FL, Vanacker JM. Estrogen-related receptor α decreases RHOA stability to induce orientated cell migration. *Proc Natl Acad Sci U S A*. 2014 Oct 21;111(42):15108-13. doi: 10.1073/pnas.1402094111. Epub 2014 Oct 6.
5. Perry MC, Dufour CR, Eichner LJ, Tsang DW, Deblois G, Muller WJ, **Giguère V**. ERBB2 deficiency alters an E2F-1-dependent adaptive stress response and leads to cardiac dysfunction. *Mol Cell Biol*. 2014 Dec 1;34(23):4232-43. doi: 10.1128/MCB.00895-14. Epub 2014 Sep 22.
6. **Giguère V**. Estrogen receptor mutations in breast cancer-an anticipated "rediscovery?". *Mol Endocrinol*. 2014 Apr;28(4):427-8. doi: 10.1210/me.2014-1071. No abstract available.
7. Labbé DP, Nowak DG, Deblois G, Lessard L, **Giguère V**, Trotman LC, Tremblay ML. Prostate cancer genetic-susceptibility locus on chromosome 20q13 is amplified and coupled to androgen receptor-regulation in metastatic tumors. *Mol Cancer Res*. 2014 Feb;12(2):184-9. doi: 10.1158/1541-7786.MCR-13-0477. Epub 2013 Dec 30.

Lucy Gilbert

1. Fiset PO, Wou K, Arseneau J, **Gilbert L**. Vulvar carcinosarcoma secondary to radiotherapy: a case report and review of the literature. *J Low Genit Tract Dis*. 2014 Jul;18(3):e74-9. doi: 10.1097/LGT.0b013e3182a82115. Review.

Philip Gordon

1. Cahill C, Gordon PH, Petrucci A, Boutros M. Small bowel adenocarcinoma and Crohn's disease: any further ahead than 50 years ago? *World J Gastroenterol*. 2014 Sep 7;20(33):11486-95. doi: 10.3748/wjg.v20.i33.11486.

Walter Gotlieb

1. Lavoue V, Zeng X, Lau S, Press JZ, Abitbol J, Gotlieb R, How J, Wang Y, **Gotlieb WH**. Impact of robotics on the outcome of elderly patients with endometrial cancer. *Gynecol Oncol*. (2014) 133:566-62
2. Abitbol J, Lau S, Ramanakumar AV, Press JZ, Drummond N, Rosberger Z, Aubin S, Gotlieb R, How J, **Gotlieb WH**. Prospective quality of life outcomes following robotic surgery in gynecologic oncology. *Gynecol Oncol*. (2014) 134: 144-9
3. Rajanbabu A, Drudi L, Lau S, Press JZ, **Gotlieb WH**. Virtual reality surgical simulators – A prerequisite for robotic surgery. *Indian J Surg Oncol* (2014) 5: 125-7
4. **Laskov I, Drudi L**, Beauchamp MC, Yasmeen A, Ferenczy A, Pollak M, Gotlieb WH. Anti-diabetic doses of metformin decrease proliferation markers in tumors of patients with endometrial cancer. *Gynecol Oncol*. (2014) 134: 607-14
5. Kiely DJ, **Gotlieb WH**, Jardon K, Lau S, Press JZ. Advancing surgical simulation in gynecologic oncology: robotic dissection of a novel pelvic lymphadenectomy model. *Simul Healthc*. (2014) Dec 15 (Epub).
6. Guerrouahen BS, Pasquier J, Kaoud NA, Maleki M, Beauchamp MC, Yasmeen A, Ghiabi P, Lis R, Vidal F, Saleh A, Gotlieb WH, Rafii S, Rafii A. Akt-activated endothelium constitutes the niche for residual disease and resistance to bevacizumab in ovarian cancer. *Mol Cancer Ther*. 2014 Dec;13(12):3123-36.
7. Press JZ and **Gotlieb WH** Robotics. In “Gynecologic Oncology”, 6th edition (2014) Lippincott Williams & Wilkins, J. Berek and N Hacker editors.

Celia Greenwood

1. A Haghighi, MG Melka, M Bernard, M Abrahamowicz, GT Leonard, L Richer, M Perron, S Veillette, CJ Xu, **CMT Greenwood**, A Dias, A El-Sohemy, D Gaudet, T Paus and Z Pausova (2014). Opioid receptor mu 1 gene, fat intake and obesity in adolescence. *Mol Psychiatry*19(1):63-8; doi: 10.1038/mp.2012.179.
2. R Lui, A Montpetit, M Rousseau, SYM Wu, **CMT Greenwood**, TD Spector, M Pollak, C Polychronakos, JB Richards. (2014) Somatic Mutations Occurring in Early Development: A Monozygotic Twin Study. *Journal of Medical Genetics*. 51(1):28-34. doi: 10.1136/jmedgenet-2013-101712.
3. L Dufresne, K Oualkacha, V Forgetta, **CMT Greenwood**. (2014). Pathway Analysis, To Do or Not To Do? That is the question. In Genetic Analysis Workshop 18. *BMC Proceedings*. 8(1):S103. doi: 10.1186/1753-6561-8-S1-S103. (NSERC).
4. Cotterchio M, Lowcock E, Hudson T, **Greenwood CMT**, Gallinger S. (2014) Association between allergies and risk of pancreatic cancer. *Journal of Cancer Epidemiology, Biomarkers and Prevention*. 23(3): 469-480.
5. Changjiang Xu, Ioanna Tachmazidou, UK10K Consortium, Antonio Ciampi, Eleftheria Zeggini, **Celia MT Greenwood**. (2014) Estimating genome-wide significance for whole genome sequencing studies. *Genetic Epidemiology* doi: 10.1002/gepi.21797. (CIHR MOP - 115110).
6. Changjiang Xu, Antonio Ciampi, **Celia M.T. Greenwood**, the UK10K Consortium. (2014) Exploring the potential benefits of stratified false discovery rates for region based testing of association with rare genetic variation. *Frontiers in Genetics: Statistical Genetics and Methodology* (5):11. doi: 10.3389/fgene.2014.00011. (CIHR MOP - 115110).

7. J Jarry, D Schadendorf, **C Greenwood**, A Spatz, LC van Kempen. (2014). The validity of circulating microRNAs in oncology: five years of challenges and contradictions. *Molecular Oncology* 8(4):819-29. doi: 10.1016/j.molonc.2014.02.009.
8. Kelly M. Burkett, Brad McNeney, Jinko Graham, **Celia MT Greenwood** (2014). Using gene genealogies to detect rare variants associated with complex traits. *Human Heredity*, 2014; 78:117-130. (CIHR MOP - 115110).
9. Ewa Przybytkowski, Elizabeth Lenkiewicz, Michael T Barrett, Kathleen Klein, **Celia MT Greenwood** and Mark Basik. (2014). Chromosome-breakage genomic instability and chromothripsis in breast cancer. *BMC Genomics*, 15(1):579. doi:10.1186/1471-2164-15-579.
10. JP Fortin, A Labbe, M Lemire, BW Zanke, TJ Hudson, EJ Fertig, **CMT Greenwood**, KD Hansen. (2014). Functional normalization of 450K methylation array data improves replication in large cancer studies. *Genome Biology*, 15(11):503. doi: 10.1186/s13059-014-0503-2.
11. L. Dufresne, K. Oualkacha, V. Forgetta, **CMT Greenwood**. Pathway Analysis for Genetic Association Studies: To Do, or Not To Do, That is the Question. *BMC Proceedings*. 8(Suppl 1):S103. (17 June 2014).
12. SB Bull, J Graham, **CM Greenwood**. (2014) Statistical Genetic Modeling and Analysis of Complex Traits in Human Populations. 125-146. *Statistics in Action: A Canadian Outlook*. Editor: Jerry Lawless. Statistical Society of Canada.

Melissa Henry

1. **Henry M**, Ho A, Lambert SD, Carnevale FA, Greenfield B, MacDonald C, Mlynarek A, Zeitouni A, Rosberger Z, Hier M, Black M, Kost K, Frenkiel S. Looking beyond disfigurement: the experience of patients with head and neck cancer. *J Palliat Care*. 2014 Spring;30(1):5-15.
2. MacKinnon CJ, Smith NG, **Henry M**, Berish M, Milman E, Körner A, Copeland LS, Chochinov HM, Cohen SR. Meaning-based group counseling for bereavement: bridging theory with emerging trends in intervention research. *Death Stud*. 2014 Jan-Jun;38(1-5):137-44. doi: 10.1080/07481187.2012.738768. Epub 2013 Aug 22.

Michael Hier

1. Scheffler P, Forest VI, Leboeuf R, Florea AV, Tamilya M, Sands NB, Hier MP, Mlynarek AM, Payne RJ. Serum Thyroglobulin Improves the Sensitivity of the McGill Thyroid Nodule Score for Well-Differentiated Thyroid Cancer. *Thyroid*. 2014 May;24(5):852-7. Epub 2014 Feb 14.
2. R. Varshney, M N Pakdaman, N Sands, MP Hier, L Rochon, MJ Black, RJ Payne, Lymph node metastasis in thyroid papillary microcarcinoma: a study of 170 patients, *The Journal of Laryngology & Otology*, 1 of 4, January 15, 2014
3. Grégoire B. Morand, Sabrina Daniela da Silva, Michael P. Hier, Moulay A. Alaoui-Jamali, Insights into genetic and epigenetic determinants with impact on vitamin D signaling and cancer association studies: the case of thyroid cancer, *Front. Oncol.*, 04 November 2014 | doi: 10.3389/fonc.2014.00309

Tarek Hijal

1. Y. Kirova, **T. Hijal**, F. Campana, N. Fournier-Bidoz, A. Stilhart, R. Dendale and A. Fourquet. Whole breast radiotherapy in the lateral decubitus position: A dosimetric and clinical solution to decrease the doses to the organs at risk (OAR). *Radiother Oncol*. 2014 Mar;110(3):477-81.
2. S. Faria, N. Kopek, **T. Hijal**, S. Liberman, P. Charlebois, B. Stein, S. Meterissian, A. Meguerditchian, Z. Fawaz and G. Artho. Phase II trial of short-course radiotherapy followed by delayed surgery for locoregionally advanced rectal cancer. *Colorectal Dis*. 2014 Feb;16(2):O66-70.

Vera Hirsh

1. Laurie SA, Goss G, Shepherd F, Reaume M N, Nicholas G, Philip L, Wang L, Schwock J, **Hirsh V**, Oza A, Tsao MS, Wright JJ, and Leighl NB: A Phase II Trial of Saracatinib, an Inhibitor of SRC Kinases, in Previously-Treated Advanced Non-Small Cell Lung Cancer: The Princess Margaret Hospital Phase II Consortium. *Clinical Lung Cancer* 15(1): 52-57, January 2014.
2. Jänne PA, Paz-Ares L, Oh Y, Eschbach C, **Hirsh V**, Enas N, Brail L and von Pawel J: Randomised, Double-Blind, Phase II Trial Comparing Gemcitabine-Cisplatin plus the LTB4 Antagonist LY293111 versus Gemcitabine-Cisplatin plus Placebo in First-Line Non-Small Cell Lung Cancer. *Journal of Thoracic Oncology* 9(1):126-31, January 2014.
3. **Hirsh V**, Okamoto I, Hon JK, Page RD, Orsini J, Sakai H, Zhang H, Renschler MF and Socinski MA: Patient –Reported Neuropathy and Taxane-Associated Symptoms in a Phase III Trial of Nab-Paclitaxel Plus Carboplatin versus Solvent-Based Paclitaxel Plus Carboplatin for Advanced Non-Small Cell Lung Cancer. *Journal of Thoracic Oncology* (1):83-90, January 2014.
4. **Hirsh V**: Nab-Paclitaxel for the Management of Patients with Advanced Non-Small-Cell Lung Cancer. *Expert Review of Anticancer Therapy* 14(2): 129-141, February 2014.
5. Henry D, Vadhan-Raj S, **Hirsh V**, von Moos R, Hungria V, Costa L, Woll PJ, Scagliotti G, Smith G, Feng A, Jun S, Dansey R, and Yeh H: Delaying Skeletal-Related Events in a Randomised Phase III Study of Denosumab versus Zoledronic Acid in Patients with Advanced Cancer: An Analysis of Data From Patients with Solid Tumors. *Support Care Cancer* 22(3): 679-687, March 2014.
6. **Hirsh V**: Targeted treatments of bone metastases in patients with lung cancer. *Front Oncol* 4: 146, June 2014, eCollection. Review.
7. **Hirsh V**: Is the evaluation of quality of life in NSCLC trials important? Are the results to be trusted? *Front Oncol* 4: 173, July 2014, eCollection. Review.
8. Blais N, and **Hirsh V**: Chemotherapy in metastatic NSCLC – new regimens (Pemetrexed, Nab-Paclitaxel). *Front Oncol* 4: 177, July 2014, eCollection. Review.
9. Melosky B, and **Hirsh V**: Management of common toxicities in metastatic NSCLC related to anti-lung cancer therapies with EGFR-TKIs. *Front Oncol* 4: 238, September 2014, eCollection. Review.
10. Langer CJ, **Hirsh V**, Ko A, Renschler MF, and Socinski MA. Weekly nab-Paclitaxel in combination with Carboplatin as first-line therapy in patients with advanced non-small cell lung cancer: analysis of safety and efficacy in patients with renal impairment. *Clin Lung Cancer pii: S1525-7304(14)00191-0*, September 2014.

11. Blackhall F, Kim DW, Besse B, Nokihara H, Han JY, Wilner KD, Reisman A, Iyer S, **Hirsh V**, and Shaw AT. Patient-reported outcomes and quality of life in PROFILE 1007: a randomized trial of crizotinib compared with chemotherapy in previously treated patients with ALK-positive advanced non-small cell lung cancer. *J Thorac Oncol* 9(11): 1625-1633, November 2014.

Thomas Hutchinson

1. Allen, D., Badro, V., Denyer-Willis, L., Macdonald, M.E., Pare, A., **Hutchinson, T.**, Barre, P., Beauchemin, R., Bocti, H., Broadbent, A., Cohen, S.R. Fragmented care and whole-person illness: Decision-making for people with chronic end-stage kidney disease. *Chronic Illness* 2014;0(0):1–12. DOI: 10.1177/1742395314562974.

Kris Jardon

1. Gremeau AS, Bourdel N, **Jardon K**, Rabischong B, Mage G, Pouly JL, Canis M. Surgical management of non-epithelial ovarian malignancies: advantages and limitations of laparoscopy. *Eur J Obstet Gynecol Reprod Biol.* 2014 Jan;172:106-10. doi: 10.1016/j.ejogrb.2013.10.023. Epub 2013 Nov 11.

Nathalie Johnson

1. Varga C, Holcroft C, Kezouh A, Bucatel S, **Johnson N**, Petrogiannas-Haliotis T, Assouline S. Comparison of outcomes among patients aged 80 and over and younger patients with diffuse large B cell lymphoma: a population based study. *Leuk Lymphoma.* 2014 Mar;55(3):533-7
2. Chambwe N, Kormaksson M, Geng H, De S, Michor F, **Johnson NA**, Morin R, Scott DW, Godley LA, Gascoyne RD, Melnick A, Campagne F, Shaknovich R. Variability in DNA methylation defines novel epigenetic subgroups of DLBCL associated with different clinical outcomes. *Blood.* 2014 Mar 13;123(11):1699-708.
3. Nielsen TH, Diaz Z, Christodoulouopoulos R, Charbonneau F¹, Qureshi S, Rousseau C, Benlimame N, Camlioglu E, Constantin AM, Oros KK, Krumsiek J, Crump M, Morin RD, Cerchiatti L, **Johnson NA**, Haliotis TP, Miller, Jr. WH, Assouline S, Mann KK. Methods for sample acquisition and processing of serial blood and tumour biopsies for multi-center diffuse large B-cell lymphoma clinical trials. Accepted in *CANCER EPIDEMIOLOGY, Biomarkers & Prevention* Aug 18th 2014.
4. Chan FC, Telenius A, Healy S, Ben-Neriah S, Mottok A, Lim R, Drake M, Hu S, Ding J, Ha G, Scott DW, Kridel R, Bashashati A, Rogic S, **Johnson N**, Morin RD, Rimsza LM, Sehn L, Connors JM, Marra MA, Gascoyne RD, Shah SP, Steidl C. An RCOR1 loss-associated gene expression signature identifies a prognostically significant DLBCL subgroup. *Blood.* 2014 Nov 13. pii: blood-2013-06-507152.

Petr Kavan

1. Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Carpentier AF, Hoang-Xuan K, **Kavan P**, Cernea D, Brandes AA, Hilton M, Abrey L, Cloughesy T. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. *N Engl J Med.* 2014 Feb 20;370(8):709-22.
2. Henriques L, Palumbo M, Guay MP, Bahoric B, Basik M, **Kavan P**, Batist G. Imiquimod in the treatment of breast cancer skin metastasis. *J Clin Oncol.* 2014 Mar 10;32(8):e22-5.

3. Reardon DA, Nabors LB, Mason WP, Perry JR, Shapiro W, **Kavan P**, Mathieu D, Phuphanich S, Cseh A, Fu Y, Cong J, Wind S, Eisenstat DD; on behalf of the BI 1200.36 Trial Group and the Canadian Brain Tumour Consortium. Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma. *Neuro Oncol*. 2014 Aug 19. pii: nou160. [Epub ahead of print]

Neil Kopek

1. Faria S1, **Kopek N**, Hijal T, Liberman S, Charlebois P, Stein B, Meterissian S, Meguerditchian A, Fawaz Z, Artho G. Phase II trial of short-course radiotherapy followed by delayed surgery for locoregionally advanced rectal cancer. *Colorectal Dis*. 2014 Feb;16(2):O66-70. doi: 10.1111/codi.12466.

Antonis Koromilas

1. Krishnamoorthy J, Rajesh K, Mirzajani F, Kesoglidou P, Papadakis AI, **Koromilas AE** (2014) "Evidence for eIF2 α phosphorylation-independent effects of GSK2656157, a novel catalytic inhibitor of PERK with clinical implications." *Cell Cycle* 13:801-806.
2. Guan BJ, Krokowski D, Majumder M, Yuan CL, Kimball SR, Merrick WC, **Koromilas AE**, Hatzoglou M. (2014) "Translational control during endoplasmic reticulum stress beyond phosphorylation of the translation initiation factor eIF2 α ." *J. Biol. Chem.* 289:12593-611.
3. **Koromilas AE** (2014) "The roles of the translation initiation factor eIF2 α serine 51 phosphorylation in cancer formation and treatment." *Biochim Biophys Acta* Dec 11. pii: S1874-9399(14)00301-0. doi: 10.1016/j.bbagr. 2014.12.007. [Epub ahead of print] Review

Susie Lau

1. **Lau S**, Aubin S, Rosberger Z, Gourdji I, How J, Gotlieb R, Drummond N, Eniu I, Abitbol J, Gotlieb W. Health-related quality of life following robotic surgery: a pilot study. *J Obstet Gynaecol Can*. 2014 Dec;36(12):1071-8.
2. Kiely DJ, Gotlieb WH, Jardon K, **Lau S**, Press JZ. Advancing surgical simulation in gynecologic oncology: robotic dissection of a novel pelvic lymphadenectomy model. *Simul Healthc*. 2015 Feb;10(1):38-42. doi: 10.1097/SIH.0000000000000054.
3. Tsoref D, Welch S, **Lau S**, Biagi J, Tonkin K, Martin LA, Ellard S, Ghatage P, Elit L, Mackay HJ, Allo G, Tsao MS, Kamel-Reid S, Eisenhauer EA, Oza AM. Phase II study of oral ridaforolimus in women with recurrent or metastatic endometrial cancer. *Gynecol Oncol*. 2014 Nov;135(2):184-9. doi: 10.1016/j.ygyno.2014.06.033. Epub 2014 Aug 28.
4. Rajanbabu A, Drudi L, **Lau S**, Press JZ, Gotlieb WH. Virtual reality surgical simulators- a prerequisite for robotic surgery. *Indian J Surg Oncol*. 2014 Jun;5(2):125-7. doi: 10.1007/s13193-014-0314-7. Epub 2014 May 30.
5. Abitbol J, **Lau S**, Ramanakumar AV, Press JZ, Drummond N, Rosberger Z, Aubin S, Gotlieb R, How J, Gotlieb WH. Prospective quality of life outcomes following robotic surgery in gynecologic oncology. *Gynecol Oncol*. 2014 Jul;134(1):144-9. doi: 10.1016/j.ygyno.2014.04.052. Epub 2014 May 4.
6. Lavoue V, Zeng X, **Lau S**, Press JZ, Abitbol J, Gotlieb R, How J, Wang Y, Gotlieb WH. Impact of robotics on the outcome of elderly patients with endometrial cancer. *Gynecol Oncol*. 2014 Jun;133(3):556-62. doi: 10.1016/j.ygyno.2014.03.572. Epub 2014 Apr 4.

7. Rosberger Z, Krawczyk A, Stephenson E, **Lau S**. HPV vaccine education: enhancing knowledge and attitudes of community counselors and educators. *J Cancer Educ*. 2014 Sep;29(3):473-7. doi: 10.1007/s13187-013-0572-z.

Ives Levesque

1. Tourdias, T., Saranathan, M., **Levesque, I. R.**, Su, J. and Rutt, B. K. Visualization of intrathalamic nuclei with optimized white-matter-nulled MPRAGE at 7T. *Neuroimage* 84: 534-545 (2014).

Sender Liberman

1. Deckelbaum DL, Gosselin-Tardif A, Ntakiyiruta G, **Liberman S**, Vassiliou M, Rwamasirabo E, Gasakure E, Fata P, Khwaja K, Razek T, Kyamanywa P, An innovative paradigm for surgical education programs in resource limited settings, *Can J Surg*. 2014 Oct; 57(5):298-9.
2. Gillis C, Li C, Lee L, Awasthi R, Augustin B, Gamsa A, **Liberman AS**, Stein B, Charlebois P, Feldman LS, Carli F, Prehabilitation versus Rehabilitation: A Randomized Control Trial in Patients Undergoing Colorectal Resection for Cancer, *Anesthesiology*, November 2014 - Volume 121 - Issue 5 - p 937–947.
3. Melich G, Hong YK, Kim J, Hur H, Baik SH, Kim NK, **Liberman AS**, Min BS, Simultaneous development of laparoscopy and robotics provides acceptable perioperative outcomes and shows robotics to have a faster learning curve and to be overall faster in rectal cancer surgery: analysis of novice MIS surgeon learning curves, *Surgical Endoscopy*, (accepted June 2014, published online 17 July, 2014).
4. Lee L, Mata J, Augustin BR, Ghitulescu G, Boutros M, Charlebois P, Stein B, **Liberman AS**, Fried GM, Morin N, Carli F, Latimer E, Feldman LS, Cost-Effectiveness of Enhanced Recovery versus Conventional Perioperative Management for Colorectal Surgery, *Annals of Surgery*, (accepted for publication August 24, 2014)
5. Gillis C, Nguyen TH, **Liberman AS**, Carli F, Nutrition Adequacy in Enhanced Recovery After Surgery: A Single Academic Center Experience, *Nutrition in Clinical Practice (ASPEN)*, Published online Dec. 30, 2014 ahead of print.

Carmen Loiselle

1. *Arbour, C., Choinière, M., Topolovec-Vranic, J., **Loiselle, C.G.**, Puntillo, K., & Gélinas, C. (2014). Detecting pain in traumatic brain injured patients with different levels of consciousness during common procedures in the ICU: Typical or atypical behaviors? *Clinical Journal of Pain*, 30(11) 960-969.
2. Chaturvedi, S. K., Stroschein, F. J., Saraf, G., & **Loiselle, C. G.** (2014) Communication in cancer care: Psycho social, interactional, cultural, and technological issues. A general overview and the example of India. *Frontiers in Psychology*, 5. URL=http://www.frontiersin.org/Journal/Abstract.aspx?s=944&name=psychology_for_clinical_settings&ART_DOI=10.3389/fpsyg.2014.01332
3. De Souza, A., Groleau, D., **Loiselle, C.G.**, Foulkes, F., & Wong, N. (2014). Cultural Aspects of Healthy BRCA Carriers From Two Ethnocultural Groups. *Qualitative Health Research (QHR)*, 24(5) 665-681. doi:10.1177/1049732314528756

4. *Arbour, C., Choinière, M., Topolovec-Vranic, J., **Loiselle, C.G.**, & Gélinas, C. (2014). Can fluctuations in vital signs be used for pain assessment in nonverbal ICU patients with a traumatic brain injury? *Pain Research and Treatment*. vol. 2014, Article ID 175794, 11 pages, 2014. doi:10.1155/2014/175794.

Koren Mann

1. Alicia M. Bolt, Valérie Sabourin, Manuel Flores Molina, Alice M. Police, Luis Fernando Negro Silva, Dany Plourde, Maryse Lemaire, Josie Ursini-Siegel, and **Koren K. Mann**. (2015). Tungsten targets the tumor microenvironment to enhance breast cancer metastasis. *Toxicological Sciences*. 143(1): 165-77.
2. Torsten Holm Nielsen, Zuanel Diaz, Rosa Christodoulopoulos, Fredrick Charbonneau, Samia Qureshi, Caroline Rousseau, Naciba Benlimame, Errol Camlioglu, André Marc Constantin, Kathleen Klein Oros, Jan Krumsiek, Michael Crump, Ryan D. Morin, Leandro Cerchietti, Nathalie A. Johnson, Tina Petrogiannis-Halioitis, Wilson H. Miller, Jr., Sarit Assouline, **Koren K. Mann**. (2014). Methods for sample acquisition and processing of serial blood and tumour biopsies for multi-center diffuse large B-cell lymphoma clinical trials. *Cancer Epidemiology, Biomarkers, and Prevention*. 23(12): 2688-93.
3. Maryse Lemaire, Catherine A. Lemarié, Manuel Flores Molina, Cynthia Guilbert, Stéphanie Lehoux and **Koren K. Mann**. (2014). Inhibition of LXRalpha prevents arsenic-enhanced atherosclerosis, but not arsenic-altered plaque composition. *Toxicological Sciences*. 142(2): 477-88.
4. Garnier N , Redstone GG , Dahabieh MS , Nichol JN , Del Rincon SV , Gu Y , Bohle DS , Sun Y, Conklin DS , **Mann KK** , Miller WH. (2014). The Novel Arsenical Darinaparsin is Transported by Cystine Importing Systems. *Molecular Pharmacology*. 85(4): 576-85.

Luke McCaffrey

1. Archibald A, Mihai C, Macara IG, **McCaffrey L**. (2014). Oncogenic suppression of apoptosis uncovers a Rac1/JNK proliferation pathway activated by loss of Par3. *Oncogene*. Aug 11;0 [Epub ahead of print] (Published)
2. Halaoui R, **McCaffrey L**. (2014). Rewiring cell polarity signaling in cancer. *Oncogene*. Mar 17 [Epub ahead of print] (Published).
3. Chatterjee SJ, **McCaffrey L**. (2014). Emerging role of cell polarity proteins in breast cancer progression and metastasis. *Breast cancer*. 6: 15-27.

Christopher McKinnon

1. Fasse, L., Sultan, S., Flahault, C. **MacKinnon, C. J.**, S., Brédart, A., & Dolbeault, S. (2014). How do researchers conceive of spousal grief after cancer? A systematic review of models used by researchers to study spousal grief in the cancer context. *Psycho-Oncology*, 23 (2), 131-142. DOI: 10.1002/pon.3412.

Ari Meguerditchian

1. Kremer R, Gagnon B, **Meguerditchian AN**, Nadeau L, Mayo N. Effect of oral bisphosphonates for osteoporosis on development of skeletal metastases in women with breast cancer: results from a pharmaco-epidemiological study. *J Natl Cancer Inst*. 2014 Oct 2;106(11). pii: dju264. doi: 10.1093/jnci/dju264. Print 2014 Nov.

2. Trabulsi N, Riedel K, Winslade N, Gregoire JP, Meterissian S, Abrahamovicz M, Tamblyn R, Mayo N, **Meguerditchian A**. Adherence to anti-estrogen therapy in seniors with breast cancer: how well are we doing? *Breast J*. 2014 Nov-Dec;20(6):632-8. doi: 10.1111/tbj.12328. Epub 2014 Sep 23.
3. Rodriguez Rivera AM, Alabbas H, Ramjaun A, **Meguerditchian AN**. Value of positron emission tomography scan in stage III cutaneous melanoma: a systematic review and meta-analysis. *Surg Oncol*. 2014 Mar;23(1):11-6. doi: 10.1016/j.suronc.2014.01.002. Epub 2014 Jan 26. Review.
4. Krotneva SP, Ramjaun A, Reidel KE, Egual T, Trabulsi N, Mayo N, Tamblyn R, **Meguerditchian AN**. Use of hormonal therapy in senior breast cancer patients treated with or without radiotherapy. *Curr Oncol*. 2014 Feb;21(1):e105-15. doi: 10.3747/co.21.1605.
5. Faria S, Kopek N, Hijal T, Liberman S, Charlebois P, Stein B, Meterissian S, **Meguerditchian A**, Fawaz Z, Artho G. Phase II trial of short-course radiotherapy followed by delayed surgery for locoregionally advanced rectal cancer. *Colorectal Dis*. 2014 Feb;16(2):O66-70. doi: 10.1111/codi.12466.

Sarkis Meterissian

1. Faria S., Kopek N., Hijal T., Liberman S., Charlebois P., Stein B., **Meterissian S.**, Meguerditchian A., Fawaz Z. and Artho G. 2014 Phase II trial of short-course radiotherapy followed by delayed surgery for locoregionally advanced rectal cancer *Colorectal Dis* 16: O66-70.
2. Hsieh H., Paquette F., Feldman L., Fraser S., **Meterissian S.**, Fried G. And Bergman S. 2014 Formal research training during surgical residency: scaffolding for academic success. *Am. J. Surg* 207: 141-145
3. **Meterissian S.H.** 2014 The acquisition of competence in the management of Breast Diseases in the era of competency-based surgical education *World Journal of Surgery*, 38: 1423-1424.
4. Doyle K., Young M. and **Meterissian S.** 2014 Evaluation of Residency Programs:A novel approach using simulation *Journal of Graduate Medical Education* 6:55-60
5. Sabiston C. M., Brunet J., Vallance J. K., & **Meterissian S.** 2014 Prospective examination of objectively-assessed physical activity and sedentary time after breast cancer treatment: *Sitting on the crest of the teachable moment*. *Cancer Epidemiol Biomarkers Prev* 23: 1324-1330
6. Mesurolle B., Perez J.C., Azzumea F., Lemercier E., Xie X., Aldis A., Omeroglu A. and **Meterissian S.** 2014 Atypical ductal hyperplasia diagnosed at sonographically guided core needle biopsy: frequency, final surgical outcome and factors associated with underestimation. *Am. J. Roentgenol*. 202: 1389-1394
7. Alsharif S., Daghistani R., Kamberoglu E.A., Omeroglu A., **Meterissian S.** and Mesurolle B. 2014 Mammographic sonographic and MR imaging features of invasive micropapillary breast cancer. *Eur. J. Radiol*. 83: 1375-1380
8. Sun S., Hennessey H., Kam Nakch I., AlSharif S., **Meterissian S.** and Mesurolle B. 2014 Compression-refractory breast hematoma secondary to pseudoaneurysm after stereotactically guided vacuum-assisted biopsy: the critical role of urgent surgical evacuation. *J. Clin. Ultrasound* 42: 492-494

9. Trabulsi N., Riedel K., Winslade N., Gregoire J.P., **Meterissian S.**, Abrahamovicz M., Tamblyn R., Mayo N. and Meguerditchian A. 2014 Adherence to anti-estrogen therapy in seniors with breast cancer: how well are we doing? *Breast J.* 20: 632-638
10. Dumitra S., Wong S.M., **Meterissian S.**, Featherstone R., Barkun J. and Fata P. 2014 The operative dictation: a review of how this skill is taught and assessed in surgical residency programs. *J. Surg. Educ Nov 14th* (Epub ahead of print)

Catalin Mihalcioiu

1. Rodic S, **Mihalcioiu C**, Saleh RR. Detection methods of circulating tumor cells in cutaneous melanoma: a systematic review. *Crit Rev Oncol Hematol.* 2014 Jul;91(1):74-92. doi: 10.1016/j.critrevonc.2014.01.007. Epub 2014 Jan 24. Review.

Wilson Miller

1. Garnier N, Redstone G, Dahabieh MS, Nichol JN, del Rincon SV, Gu Y, Bohle DS, Sun Y, Conklin DS, Mann KK and **Miller WH Jr.** The Novel Arsenical Darinaparsin is Transported by Cystine Importing Systems. *Molecular Pharmacology* 85(4):576-85, 2014.
2. Bhatia S, Curti B, Ernstoff MS, Gordon M, Heath EI, **Miller WH Jr.**, Puzanov I, Quinn DI, Flaig TW, VanVeldhuizen P, Byrnes-Blake K, Freeman JA, Bittner R, Hunder N, Souza S and Thompson JA. Recombinant Interleukin-21 plus Sorafenib for Metastatic Renal Cell Carcinoma: A Phase 1/2 Study. *Journal for ImmunoTherapy of Cancer.* 2:2 doi:10.1186/2051-1426-2-2, 2014.
3. Larkin J, Del Vecchio M, Ascierto PA, Krajsova I, Schachter J, Neyns B, Espinosa E, Garbe C, ChiarionSileni V, Gogas H, **Miller WH Jr.**, Mandalà M, Hossain G A P, Arance A, Queirolo P, Hauschild A, Brown MP, Mitchell L, Veronese L, Blank C U. Vemurafenib in BRAFV600mutant metastatic melanoma: an open-label, multicentre safety study of 3222 patients. *Lancet Oncology.* 15(4):436-44, 2014.
4. Robichaud N, del Rincon SV, Huor B, Alain T, Petruccioli A, Hearnden J, Goncalves C, Grotegut S, Spruck CH, Furic L, **Miller WH Jr.**, Sonenberg N. Phosphorylation of eIF4E promotes EMT and metastasis via translational control of SNAIL and MMP-3. *Oncogene*, 2014 Jun 9. doi: 10.1038/onc.2014.146. [Epub ahead of print].
5. Zahreddine HA, Culjkovic-Kraljacic B, Assouline S, Gendron P, Romeo AA, Morris SJ, Cormack G, Jaquith JB, and Cerchietti L, Cocolakis E, Bergeron J, Leber B, Becker MW, Pei S, Jordan CT, **Miller WH Jr.** and Borden KLB. The sonic hedgehog factor Gli1 imparts drug resistance through inducible glucuronidation. *Nature.* 3;511(7507):90-3, 2014.
6. Grob JJ, Amonkar MM, Martin-Algarras S, Demidov LV, Goodman V, Grotzinger K, Haney P, Kämpgen E, Karaszewska B, Mauch C, **Miller WH Jr.**, Millward M, Mirakhur B, Rutkowski P, Chiarion-Sileni V, Swann S, Hauschild A. Patient Perception of the Benefit of a BRAF Inhibitor in Metastatic Melanoma: Quality of Life Analyses of the BREAK-3 Study Comparing Dabrafenib With DTIC. *Ann Oncol* 2014 Jul;25(7):1428-36.
7. Nielsen TH, Diaz Z, Christodoulopoulos R, Charbonneau F, Qureshi S, Rousseau C, Benlimame N, Camlioglu E, Constantin AM, Oros KK, Krumsiek J, Crump M, Morin RD, Cerchietti L, Johnson NA, Petrogiannis-Haliotis T, **Miller WH Jr.**, Assouline S, Mann KK. Methods for sample acquisition and processing of serial blood and tumour biopsies for multi-center diffuse large B-cell lymphoma clinical trials. *Cancer Epidemiology, Biomarkers, and Prevention.* 23(12):2688-93, 2014.

8. Pettersson F, del Rincon SV, **Miller WH Jr.** Eukaryotic translation initiation factor 4E as a novel therapeutic target in hematological malignancies and beyond. Expert Opinion on Therapeutic Targets. 18(9):1035-48, 2014.
9. Nichol J N, Garnier N, **Miller WH Jr.** Triple A Therapy: The Molecular Underpinnings of the Unique Sensitivity of Leukemic Promyelocytes to Anthracyclines, All-Trans Retinoic Acid and Arsenic Trioxide. *Best Practice & Research Clinical Haematology*. 27(1): 19-31, 2014.

Thierry Muanza

1. Tamim Niazi, Gary Mok, Mitra Heravi, Te Vuong, Raquel Aloyz, Lawrence Panasci, **Thierry Muanza**. Effects of DNA-PK inhibition on DNA repair and cell survival in irradiated gastric cancer cell line N87. *Current Oncology* 2014 Apr;21(2):91-6.

Alain Nepveu

1. Ramdzan, Z., R. Pal, C. Vadnais, G. Vandal, C. Cadieux, L. Leduy, S. Davoudi, L. Yao, A. K. Karnesis, M. Paquet, D. Dankort, and **A. Nepveu**. RAS-Transformation in Cancer Cells Requires CUX1-Dependent Repair of Oxidative DNA Damage. *PLoS Biology* 12 (3), e1001807. 2014.
2. Ramdzan, Z., and **A. Nepveu**. CUX1, a Haploinsufficient Tumour Suppressor Gene Overexpressed in Advanced Cancers. Invited review for *Nature Reviews Cancer* 14: 673-682. 2014.
3. Vadnais, C., Shooshtarizadeh, P., Rajadurai, C. V., Lesurf, R., Hulea, L., Davoudi, S., Cadieux, C., Hallett, M., Park, M. and **Nepveu, A.** (2014). Autocrine Activation of the Wnt/beta-Catenin Pathway by CUX1 and GLIS1 in Breast Cancers. *Biology Open*, <http://bio.biologists.org/content/3/10/937.long>. published online 12 September, 2014.

Sylvain Néron

1. **Néron S**, Perez S, Benc R, Bellman A, Rosberger Z, Vuong T. The experience of pain and anxiety in rectal cancer patients during high-dose-rate brachytherapy. *Curr Oncol*. 2014 Feb;21(1):e89-95. doi: 10.3747/co.21.1741.

Scott Owen

1. **Owen S**, Souhami L. "The Management of brain metastases in non-small cell lung cancer". *Front Oncol*. 2014 Sep 15;4:248.

Lawrence Panasci

1. Esfahani K, Ferrario C, Le P, **Panasci L**. The trastuzumab and vinorelbine combination: an alternative to taxane-based chemotherapy for early-stage and locally advanced her2-positive breast cancer. *Curr Oncol*. 2014 Oct;21(5):e723-7. doi: 10.3747/co.21.2069.
2. Le P, Garg A, Brandao G, Abu-Sanad A, **Panasci L**. Hormonal manipulation with letrozole in the treatment of metastatic malignant pecoma. *Curr Oncol*. 2014 Jun;21(3):e518-20. doi: 10.3747/co.21.1849.
3. Esfahani K, Ferrario C, Le P, **Panasci L**. Aromatase inhibition in relapsing low malignant potential serous tumours of the ovary. *BMJ Case Rep*. 2014 Jun 12;2014. pii: bcr2014204287. doi: 10.1136/bcr-2014-204287.

4. Niazi MT, Mok G, Heravi M, Lee L, Vuong T, Aloyz R, **Panasci L**, Muanza T. Effects of dna-dependent protein kinase inhibition by NU7026 on dna repair and cell survival in irradiated gastric cancer cell line N87. *Curr Oncol.* 2014 Apr;21(2):91-6. doi: 10.3747/co.21.1509.
5. Katherine E. Bujold, Johans Fakhoury, Thomas G. W. Edwardson, Karina M. M. Carneiro, Joel Neves Briard, Antoine G. Godin, Lilian Amrein, Graham D. Hamblin, **Lawrence C. Panasci**, Paul W. Wiseman and Hanadi F. Sleiman. Sequence-responsive unzipping DNA cubes with tunable cellular uptake profiles. *Chem. Sci.*, 2014,5, 2449-2455

Morag Park

1. Guo J, Canaff L, Rajadurai CV, Fils-Aimé N, Tian J, Dai M, Korah J, Villatoro M, **Park M**, Ali S, Lebrun JJ. Breast cancer anti-estrogen resistance 3 inhibits transforming growth factor β /Smad signaling and associates with favorable breast cancer disease outcomes. *Breast Cancer Res.* 2014 Dec 13;16(6):476. doi: 10.1186/s13058-014-0476-9.
2. Havrylov S, **Park M**. MS/MS-based strategies for proteomic profiling of invasive cell structures. *Proteomics.* 2015 Jan;15(2-3):272-86. doi: 10.1002/pmic.201400220. Epub 2014 Dec 15.
3. Tofigh A, Suderman M, Paquet ER, Livingstone J, Bertos N, Saleh SM, Zhao H, Souleimanova M, Cory S, Lesurf R, Shahalizadeh S, Garcia Lopez N, Riazalhosseini Y, Omeroglu A, Ursini-Siegel J, **Park M**, Dumeaux V, Hallett M. The prognostic ease and difficulty of invasive breast carcinoma. *Cell Rep.* 2014 Oct 9;9(1):129-42. doi: 10.1016/j.celrep.2014.08.073. Epub 2014 Oct 2.
4. Vadnais C, Shooshtarizadeh P, Rajadurai CV, Lesurf R, Hulea L, Davoudi S, Cadieux C, Hallett M, **Park M**, Nepveu A. Autocrine Activation of the Wnt/ β -Catenin Pathway by CUX1 and GLIS1 in Breast Cancers. *Biol Open.* 2014 Sep 12;3(10):937-46. doi: 10.1242/bio.20148193.
5. Hudson J, Ha JR, Sabourin V, Ahn R, La Selva R, Livingstone J, Podmore L, Knight J, Forrest L, Beauchemin N, Hallett M, **Park M**, Ursini-Siegel J. p66ShcA promotes breast cancer plasticity by inducing an epithelial-to-mesenchymal transition. *Mol Cell Biol.* 2014 Oct 1;34(19):3689-701. doi: 10.1128/MCB.00341-14. Epub 2014 Jul 28.
6. Lai AZ, Cory S, Zhao H, Gigoux M, Monast A, Guiot MC, Huang S, Tofigh A, Thompson C, Naujokas M, Marcus VA, Bertos N, Sehat B, Perera RM, Bell ES, Page BD, Gunning PT, Ferri LE, Hallett M, **Park M**. Dynamic reprogramming of signaling upon met inhibition reveals a mechanism of drug resistance in gastric cancer. *Sci Signal.* 2014 Apr 22;7(322):ra38. doi: 10.1126/scisignal.2004839.

Jerry Pelletier

1. Malina A, Katigbak A, Cencic R, Maïga RI, Robert F, Miura H, **Pelletier J**. Adapting CRISPR/Cas9 for functional genomics screens. *Methods Enzymol.* 2014;546:193-213. doi: 10.1016/B978-0-12-801185-0.00010-6.
2. Fukao A, Mishima Y, Takizawa N, Oka S, Imataka H, **Pelletier J**, Sonenberg N, Thoma C, Fujiwara T. MicroRNAs trigger dissociation of eIF4AI and eIF4AII from target mRNAs in humans. *Mol Cell.* 2014 Oct 2;56(1):79-89. doi: 10.1016/j.molcel.2014.09.005.

3. Cencic R, Miura H, Malina A, Robert F, Ethier S, Schmeing TM, Dostie J, **Pelletier J**. Protospacer adjacent motif (PAM)-distal sequences engage CRISPR Cas9 DNA target cleavage. *PLoS One*. 2014 Oct 2;9(10):e109213. doi: 10.1371/journal.pone.0109213. eCollection 2014.
4. Chu J, **Pelletier J**. Targeting the eIF4A RNA helicase as an anti-neoplastic approach. *Biochim Biophys Acta*. 2014 Sep 16. pii: S1874-9399(14)00247-8. doi: 10.1016/j.bbagr.2014.09.006. [Epub ahead of print] Review.
5. Robert F, Roman W, Bramoullé A, Fellmann C, Roulston A, Shustik C, Porco JA Jr, Shore GC, Sebag M, **Pelletier J**. Translation initiation factor eIF4F modifies the dexamethasone response in multiple myeloma. *Proc Natl Acad Sci U S A*. 2014 Sep 16;111(37):13421-6. doi: 10.1073/pnas.1402650111. Epub 2014 Sep 2.
6. Wolfe AL, Singh K, Zhong Y, Drewe P, Rajasekhar VK, Sanghvi VR, Mavrakis KJ, Jiang M, Roderick JE, Van der Meulen J, Schatz JH, Rodrigo CM, Zhao C, Rondou P, de Stanchina E, Teruya-Feldstein J, Kelliher MA, Speleman F, Porco JA Jr, **Pelletier J**, Rättsch G, Wendel HG. RNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancer. *Nature*. 2014 Sep 4;513(7516):65-70. doi: 10.1038/nature13485. Epub 2014 Jul 27.
7. Lee T, Di Paola D, Malina A, Mills JR, Kreps A, Grosse F, Tang H, Zannis-Hadjopoulos M, Larsson O, **Pelletier J**. Suppression of the DHX9 helicase induces premature senescence in human diploid fibroblasts in a p53-dependent manner. *J Biol Chem*. 2014 Aug 15;289(33):22798-814. doi: 10.1074/jbc.M114.568535. Epub 2014 Jul 2.
8. Sun Y, Atas E, Lindqvist LM, Sonenberg N, **Pelletier J**, Meller A. Single-molecule kinetics of the eukaryotic initiation factor 4AI upon RNA unwinding. *Structure*. 2014 Jul 8;22(7):941-8. doi: 10.1016/j.str.2014.04.014. Epub 2014 Jun 5.
9. Dow LE, Nasr Z, Saborowski M, Ebbesen SH, Manchado E, Tasdemir N, Lee T, **Pelletier J**, Lowe SW. Conditional reverse tet-transactivator mouse strains for the efficient induction of TRE-regulated transgenes in mice. *PLoS One*. 2014 Apr 17;9(4):e95236. doi: 10.1371/journal.pone.0095236. eCollection 2014.
10. Galicia-Vázquez G, Di Marco S, Lian XJ, Ma JF, Gallouzi IE, **Pelletier J**. Regulation of eukaryotic initiation factor 4AII by MyoD during murine myogenic cell differentiation. *PLoS One*. 2014 Jan 23;9(1):e87237. doi: 10.1371/journal.pone.0087237. eCollection 2014.

Carmela Pepe

1. Albanna AS, Kasymjanova G, Robitaille C, Cohen V, Brandao G, **Pepe C**, Small D, Agulnik J. Comparison of the yield of different diagnostic procedures for cellular differentiation and genetic profiling of non-small-cell lung cancer. *J Thorac Oncol*. 2014 Aug;9(8):1120-5. doi: 10.1097/JTO.0000000000000230.
2. Tsoukas MA, Krishnamoorthy P, Richards BJ, **Pepe C**, Christopoulos S. Adrenal suppression with cushingoid features from inhaled corticosteroid therapy in an adult asthmatic patient. *Am J Med*. 2014 May;127(5):e1-2. doi: 10.1016/j.amjmed.2013.11.024. Epub 2014 Jan 8.

Alan Peterson

1. Saeed Khalili, Denise L Faustman, Younan Liu, Yoshinori Sumita, David Blank, **Alan Peterson**, Shohta Kodama, Simon D Tran; Treatment for salivary gland hypofunction at both initial and advanced stages of Sjögren-like disease: a comparative study of bone marrow therapy versus spleen cell therapy with a 1-year monitoring period. *Cytotherapy* 01/2014

Michael Pollak

1. Bensimon L, Yin H, Suissa S, **Pollak MN**, Azoulay L. Type 2 diabetes and the risk of mortality among patients with prostate cancer. *Cancer Causes Control* 25: 329-38, 2014.
2. Borugian MJ, Spinelli JJ, Gordon PB, Abanto Z, Brooks-Wilson A, **Pollak MN**, Warren LJ, Hislop TG, Gallagher RP. Fasting insulin and endogenous hormones in relation to premenopausal breast density (Canada). *Cancer Causes Control* 25: 385-94, 2014.
3. Mireuta M, Birman E, Barmash M, **Pollak M**. Quantification of Binding of IGF-1 to BI 836845, a Candidate Therapeutic Antibody Against IGF-1 and IGF-2, and Effects of This Antibody on IGF-1:IGFBP-3 Complexes in Vitro and in Male C57BL/6 Mice. *Endocrinology* 155: 703-15, 2014.
4. Rothermundt C, Hayoz S, Templeton AJ, Winterhalder R, Strebel RT, Bärtschi D, **Pollak M**, Lui L, Endt K, Schiess R, Rüschoff JH, Cathomas R, Gillessen S. Metformin in Chemotherapy-naïve Castration-resistant Prostate Cancer: A Multicenter Phase 2 Trial (SAKK 08/09). *Eur Urol* 66: 468-74, 2014.
5. De Bono JS, Piulats JM, Pandha HS, Petrylak DP, Saad F, Antón-Aparicio LM, Sandhu SK, Fong P, Gillessen S, Hudes GR, Wang T, Scranton J, **Pollak MN**. Phase II Randomized Study of Figitumumab plus Docetaxel and Docetaxel Alone with Crossover for Metastatic Castration-Resistant Prostate Cancer. *Clin Cancer Res* 20; 1925-34, 2014.
6. Takeuchi A, Shiota M, Beraldi E, Thaper D, Takahara K, Ibuki N, **Pollak M**, Cox ME, Naito S, Gleave ME, Zoubeidi A. Insulin-like growth factor-I induces CLU expression through Twist1 to promote prostate cancer growth. *Mol Cell Endocrinol* 1; 117-125, 2014.
7. Bramwell VH, Tuck AB, Chapman JA, Anborgh PH, Postenka CO, Al-Katib W, Shepherd LE, Han L, Wilson CF, Pritchard KI, **Pollak MN**, Chambers AF. Assessment of osteopontin in early breast cancer: correlative study in a randomised clinical trial. *Breast Cancer Res* 16; 2014.
8. Cao Y, Lindström S, Schumacher F, Stevens VL, Albanes D, Berndt SI, Boeing H, Bas Bueno-de-Mesquita H, Canzian F, Chamosa S, Chanock SJ, Diver WR, Gapstur SM, Gaziano JM, Giovannucci EL, Haiman CA, Henderson B, Johansson M, Marchand LL, Palli D, Rosner B, Siddiq A, Stampfer M, Stram DO, Tamimi R, Travis RC, Trichopoulos D, Willett WC, Yeager M, Kraft P, Hsing AW, **Pollak M**, Lin X, Ma J. Insulin-like Growth Factor Pathway Genetic Polymorphisms, Circulating IGF1 and IGFBP3, and Prostate Cancer Survival. *J Natl Cancer Inst* 106; 218, 2014.
9. Lai GY, Giovannucci EL, **Pollak MN**, Peskoe SB, Stampfer MJ, Willett WC, Platz EA. Association of C-peptide and leptin with prostate cancer incidence in the Health Professionals Follow-up Study. *Cancer Causes Control* 25; 625-32, 2014.
10. Beasley JM, Wedick NM, Rajpathak SN, Xue X, Holmes MD, Gunter MJ, Wylie-Rosett J, Rohan TE, **Pollak M**, Kaplan RC, Hu FB, Sun Q, Strickler HD. Circulating IGF-axis protein levels and their relation with levels of plasma adipocytokines and macronutrient consumption in women. *Growth Horm IGF Res* 24; 142-9, 2014.
11. Joshua AM, Zannella VE, Downes MR, Bowes B, Hersey K, Koritzinsky M, Schwab M, Hofmann U, Evans A, van der Kwast T, Trachtenberg J, Finelli A, Fleshner N, Sweet J, **Pollak M**. A pilot 'window of opportunity' neoadjuvant study of metformin in localised prostate cancer. *Prostate Cancer Prostatic Dis* 17; 252-8, 2014.
12. **Pollak M**. Overcoming Drug Development Bottlenecks With Repurposing: Repurposing biguanides to target energy metabolism for cancer treatment. *Nat Med* 5; 591-593, 2014.

13. Bridges HR, Jones AJ, **Pollak MN**, Hirst J. Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria. *Biochem J* 462; 475-87, 2014.
14. Bensimon L, Yin H, Suissa S, **Pollak MN**, Azoulay L. The use of metformin in patients with prostate cancer and the risk of death. *Cancer Epidemiol Biomarkers Prev* 23; 2111-8, 2014.
15. Laskov I, Drudi L, Beauchamp MC, Yasmeen A, Ferenczy A, **Pollak M**, Gotlieb WH. Anti-diabetic doses of metformin decrease proliferation markers in tumors of patients with endometrial cancer. *Gynecol Oncol* 134; 607-14.
16. Jacobs EJ, Newton CC, Silverman DT, Nogueira LM, Albanes D, Männistö S, **Pollak M**, Stolzenberg-Solomon RZ. Serum transforming growth factor- β 1 and risk of pancreatic cancer in three prospective cohort studies. *Cancer Causes Control* 25; 1083-91, 2014.
17. Assayag J, **Pollak MN**, Azoulay L. Post-diagnostic use of beta-blockers and the risk of death in patients with prostate cancer. *Eur J Cancer* 50; 2838-45, 2014.
18. Andrzejewski S, Gravel SP, **Pollak M**, St-Pierre J. Metformin directly acts on mitochondria to alter cellular bioenergetics. *Cancer Metab.* 2014 Aug 28. *eCollection* 2014.
19. Cao Y, Nimptsch K, Shui IM, Platz EA, Wu K, **Pollak MN**, Kenfield SA, Stampfer MJ, Giovannucci EL. Prediagnostic plasma IGFBP-1, IGF-1 and risk of prostate cancer. *Int J Cancer.* 2014 Oct 27. *Epub ahead of print.*
20. DeCensi A, Puntoni M, Gandini S, Guerrieri-Gonzaga A, Johansson HA, Cazzaniga M, Pruneri G, Serrano D, Schwab M, Hofmann U, Mora S, Aristarco V, Macis D, Bassi F, Luini A, Lazzeroni M, Bonanni B, **Pollak MN**. Differential effects of metformin on breast cancer proliferation according to markers of insulin resistance and tumor subtype in a randomized presurgical trial. *Breast Cancer Res Treat* 148; 81-90, 2014.
21. Paxton RJ, Jung SY, Vitolins MZ, Fenton J, Paskett E, **Pollak M**, Hays-Grudo J, Hursting SD, Chang S. Associations between time spent sitting and cancer-related biomarkers in postmenopausal women: an exploration of effect modifiers. *Cancer Causes Control.* 2014 Sep 20. *Epub ahead of print.*
22. Foretz M, Guigas B, Bertrand L, **Pollak M**, Viollet B. Metformin: from mechanisms of action to therapies. *Cell Metab* 20; 953-966, 2014.
23. Gravel SP, Hulea L, Toban N, Birman E, Blouin MJ, Zakikhani M, Zhao Y, Topisirovic I, St-Pierre J, **Pollak M**. Serine deprivation enhances antineoplastic activity of biguanides. *Cancer Res* 74; 7521-33, 2014.
24. Chapman JA, Pritchard KI, Goss PE, Ingle JN, Muss HB, Dent SF, Vandenberg TA, Findlay B, Gelmon KA, Wilson CF, Shepherd LE, **Pollak MN**. Competing risks of death in younger and older postmenopausal breast cancer patients. *World J Clin Oncol*; 5: 1088-96, 2014.
25. Assayag J, **Pollak MN**, Azoulay L. The Use of Aspirin and the Risk of Mortality in Patients with Prostate Cancer. *J Urol.* 2014 Nov 14. *Epub ahead of print.*
26. Mayers JR, Wu C, Clish CB, Kraft P, Torrence ME, Fiske BP, Yuan C, Bao Y, Townsend MK, Tworoger SS, Davidson SM, Papagiannakopoulos T, Yang A, Dayton TL, Ogino S, Stampfer MJ, Giovannucci EL, Qian ZR, Rubinson DA, Ma J, Sesso HD, Gaziano JM, Cochrane BB, Liu S, Wactawski-Wende J, Manson JE, **Pollak MN**, Kimmelman AC, Souza A, Pierce K, Wang TJ, Gerszten RE, Fuchs CS, Vander Heiden MG, Wolpin BM. Elevation of circulating branched-chain amino acids is an early event in human pancreatic adenocarcinoma development. *Nat Med*; 20: 1193-8, 2014.

Raghu Rajan

1. Boulanger J, Boursiquot JN, Cournoyer G, Lemieux J, Masse MS, Almanric K, Guay MP and the Comité de l'évolution des pratiques en oncologie. Management of hypersensitivity to platinum- and taxane-based chemotherapy: Cepo review and clinical recommendations. *Curr Oncol*. 2014 Aug;21(4):e630-41.
2. Boily G, Villeneuve JP, Lacoursière L, Chaudhury P, Couture F, Ouellet JF, Lapointe R, Goulet S, Gervais N and the Comité de l'évolution des pratiques en oncologie. Transarterial embolization therapies for the treatment of hepatocellular carcinoma: CEPO review and clinical recommendations. *HPB (Oxford)*. 2014 Jun 24. [Epub ahead of print].

Stéphane Richard

1. Lafleur, V.N, **S. Richard** and D. Richard 2014. Transcriptional Repression of Hypoxia-inducible Factor-1 (HIF-1) by the Protein Arginine Methyltransferase, PRMT1. *Molecular Biology Cell* 25:925-35

Zeev Rosberger

1. Krawczyk A, Knäuper B, Gilca V, Dubé E, Perez S, Joyal-Desmarais K, **Rosberger Z**. Parents' decision-making about the human papillomavirus vaccine for their daughters: I. Quantitative results. *Hum Vaccin Immunother*. 2015 Feb;11(2):322-9. doi: 10.1080/21645515.2014.1004030.
2. Krawczyk A, Perez S, King L, Vivion M, Dubé E, Rosberger Z. Parents' decision-making about the human papillomavirus vaccine for their daughters: II. Qualitative results. *Hum Vaccin Immunother*. 2015 Feb;11(2):330-6. doi: 10.4161/21645515.2014.980708.
3. Lau S, Aubin S, **Rosberger Z**, Gourdji I, How J, Gotlieb R, Drummond N, Eniu I, Abitbol J, Gotlieb W. Health-related quality of life following robotic surgery: a pilot study. *J Obstet Gynaecol Can*. 2014 Dec;36(12):1071-8.
4. Shapiro GK, Joyal-Desmarais K, Perez S, **Rosberger Z**. A response to Fu et al.'s "Educational interventions to increase HPV vaccination acceptance". *Vaccine*. 2014 Nov 12;32(48):6342-4.
5. Henry M, Ho A, Lambert SD, Carnevale FA, Greenfield B, MacDonald C, Mlynarek A, Zeitouni A, **Rosberger Z**, Hier M, Black M, Kost K, Frenkiel S. Looking beyond disfigurement: the experience of patients with head and neck cancer. *J Palliat Care*. 2014 Spring;30(1):5-15.
6. Zelkowitz P, King L, Whitley R, Tulandi T, Ells C, Feeley N, Gold I, **Rosberger Z**, Chan P, Bond S, Mahutte N, Ouhilal S, Holzer H. A Comparison of Immigrant and Canadian-Born Patients Seeking Fertility Treatment. *J Immigr Minor Health*. 2014 May 13. [Epub ahead of print]
7. Abitbol J, Lau S, Ramanakumar AV, Press JZ, Drummond N, **Rosberger Z**, Aubin S, Gotlieb R, How J, Gotlieb WH. Prospective quality of life outcomes following robotic surgery in gynecologic oncology. *Gynecol Oncol*. 2014 Jul;134(1):144-9. doi: 10.1016/j.ygyno.2014.04.052. Epub 2014 May 4.
8. Lebel S, Maheu C, Lefebvre M, Secord S, Courbasson C, Singh M, Jolicoeur L, Benea A, Harris C, Fung MF, **Rosberger Z**, Catton P. Addressing fear of cancer recurrence among women with cancer: a feasibility and preliminary outcome study. *J Cancer Surviv*. 2014 Sep;8(3):485-96. doi: 10.1007/s11764-014-0357-3. Epub 2014 Apr 23.

Veena Sangwan

1. Caicedo-Granados E, Lin R, Fujisawa C, Yueh B, **Sangwan V**, Saluja A. Wild-type p53 reactivation by small-molecule Minnelide™ in human papillomavirus (HPV)-positive head and neck squamous cell carcinoma. *Oral Oncol.* 2014 Dec;50(12):1149-56.
2. Alsaied OA, **Sangwan V**, Banerjee S, Krosch TC, Chugh R, Saluja A, Vickers SM, Jensen EH. Sorafenib and triptolide as combination therapy for hepatocellular carcinoma. *Surgery.* 2014 Aug;156(2):270-9.
3. Mujumdar N, Banerjee S, Chen Z, **Sangwan V**, Chugh R, Dudeja V, Yamamoto M, Vickers SM, Saluja AK. Triptolide activates unfolded protein response leading to chronic ER stress in pancreatic cancer cells. *Am J Physiol Gastrointest Liver Physiol.* 2014 Jun 1;306(11):G1011-20.
4. Chen, Z., **Sangwan, V.**, Banerjee, S., Chugh, R., Dudeja, V., Vickers, S.M., Saluja, A.K. Triptolide sensitizes pancreatic cancer cells to TRAIL-induced activation of the Death Receptor pathway. *Cancer Lett.* 2014 Mar 21. pii: S0304-3835(14)00161-X.
5. Banerjee, S.*, Nomura, A.*, **Sangwan, V.***, Dudeja, V., Chugh, R., Vickers, S.M., Saluja, A.K. Minnelide reduces CD133+ tumor initiating cells (TIC) in a syngenic murine model of pancreatic ductal adenocarcinoma. *Clin Cancer Res.* 2014 Mar 14. *=co-first authors

Jan Seuntjens

1. McEwen, L. DeWerd, G. Ibbott, D. Followill, D. W. O. Rogers, S. Seltzer, and **J Seuntjens** (2014) *Addendum to the AAPM's TG-51 Protocol for Clinical Reference Dosimetry of High-Energy Photon Beams*, *Med Phys* **41**:041501.
2. H Bekerat, S. Devic, F. Deblois, K. Singh, A. Sarfhenia, **J Seuntjens**, S. Shih, X. Gyu, and D. Lewis (2014) *Improving the Energy Response of External Beam Therapy (EBT) GAFCHROMIC™ Dosimetry Films at Low Energies (≥ 100 keV)*, *Med Phys* **41**(2):022101. doi: 10.1118/1.4860157.
3. Tomic N, Quintero C, Whiting BR, Aldelaijan S, Bekerat H, Liang L, DeBlois F, **Seuntjens J**, Devic (2014) *Characterization of calibration curves and energy dependence GafChromic(TM) XR-QA2 model based radiochromic film dosimetry system*. *Med Phys.* 2014 Jun; **41**(6):062105. doi: 10.1118/1.4876295
4. Conneely E, Alexander A, Ruo R, Chung E, **Seuntjens J.**, Foley MJ. (2014) *Monte Carlo investigation of collapsed versus rotated IMRT plan verification*. *J Appl Clin Med Phys.* 2014 May 8;15(3):4681. doi: 10.1120/jacmp.v15i3.4681.
5. Connell T, Alexander A, Papaconstadopoulos P, Serban M, Devic S, **Seuntjens J**, (2014) *Delivery validation of an automated modulated electron radiotherapy plan*. *Med Phys.* 2014 Jun;41(6):061715. doi: 10.1118/1.4876297.
6. Connell T, **Seuntjens J**, (2014) *Design and validation of novel scattering foils for modulated electron radiation therapy*. *Phys Med Biol.* 2014 May 21;59(10):2381-91.
7. Papaconstadopoulos P, Tessier F and **Seuntjens J**, (2014) *On the correction, perturbation and modification of small field detectors in relative dosimetry*. *Phys Med Biol.* 59(19):5937-5952.
8. Jabbari K and **Seuntjens J**, (2014) *A fast Monte Carlo code for proton transport in radiation therapy based on MCNPX*. *J Med Phys* **39**(3):156-163.
9. Pater P, Bernal M. A., **Seuntjens J**, I. El Naqa (2014) *On the Consistency of Monte Carlo Track Structure DNA Damage Simulations*, *Med Phys* **41**(12):121708.

10. Papaconstadopoulos P, Hegyi G., **Seuntjens J**, and Devic S., (2014) *A protocol for EBT3 radiochromic film dosimetry using reflection scanning*, Med. Phys. 41(12): 122101.
11. Nobah A, Aldelaijan S, Devic S, Tomic N, **Seuntjens J**, Al-Shabanah M, Moftah B., (2014) *Radiochromic film based dosimetry of image-guidance procedures on different radiotherapy modalities*, J Appl Clin Med Phys. 15(6):5006.

George Shenouda

1. Chung CH, Zhang Q, Kong CS, Harris J, Fertig EJ, Harari PM, Wang D, Redmond KP, **Shenouda G**, Trotti A, Raben D, Gillison ML, Jordan RC, Le QT.J p16 protein expression and human papillomavirus status as prognostic biomarkers of non-oropharyngeal head and neck squamous cell carcinoma. Clin Oncol. 2014 Dec 10;32(35):3930-8. doi: 10.1200/JCO.2013.54.5228. Epub 2014 Sep 29.
2. Gurberg J, Bouganim N, **Shenouda G**, Zeitouni A. A case of recurrent anaplastic meningioma of the skull base with radiologic response to hydroxyurea. J Neurol Surg Rep. 2014 Aug;75(1):e52-5. doi: 10.1055/s-0033-1359300. Epub 2014 Apr 17.
3. Beitler JJ, Zhang Q, Fu KK, Trotti A, Spencer SA, Jones CU, Garden AS, **Shenouda G**, Harris J, Ang KK. Final results of local-regional control and late toxicity of RTOG 9003: a randomized trial of altered fractionation radiation for locally advanced head and neck cancer. Int J Radiat Oncol Biol Phys. 2014 May 1;89(1):13-20. doi: 10.1016/j.ijrobp.2013.12.027. Epub 2014 Mar 7.

Gayle Shinder

1. **Shinder, G.A.** Book Review – *Enigmas of Health and Disease*, Alfredo Morabia, 2014 Columbia University Press, ISBN:978-0-231-16885-4 (296 pp). Prev. Med. (2014), 69:108-109. <http://dx.doi.org/10.1016/j.ypmed.2014.08.031>
2. Franco EL, **Shinder GA**, Tota JE, Isidean SD. Striving for excellence while adapting to change: redefining our mission of serving the preventive medicine community. Prev Med. 2014 Oct;67:311-2. doi: 10.1016/j.ypmed.2014.07.021. Epub 2014 Jul 21. No abstract available.

Chaim Shustik

1. Robert F, Roman W, Bramoullé A, Fellmann C, Roulston A, **Shustik C**, Porco JA Jr, Shore GC, Sebag M, Pelletier J. Translation initiation factor eIF4F modifies the dexamethasone response in multiple myeloma. Proc Natl Acad Sci U S A. 2014 Sep 16;111(37):13421-6. doi: 10.1073/pnas.1402650111. Epub 2014 Sep 2.
2. Benboubker L, Dimopoulos MA, Dispenzieri A, Catalano J, Belch AR, Cavo M, Pinto A, Weisel K, Ludwig H, Bahlis N, Banos A, Tiab M, Delforge M, Cavenagh J, Gherdes C, Lee JJ, Chen C, Oriol A, de la Rubia J, Qiu L, White DJ, Binder D, Anderson K, Femand JP, Moreau P, Attal M, Knight R, Chen G, Van Oostendorp J, Jacques C, Ervin-Haynes A, Avet-Loiseau H, Hulin C, Facon T; **FIRST Trial Team**. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med. 2014 Sep 4;371(10):906-17. doi: 10.1056/NEJMoa1402551.

- Richardson PG, Siegel DS, Vij R, Hofmeister CC, Baz R, Jagannath S, Chen C, Lonial S, Jakubowiak A, Bahlis N, Song K, Belch A, Raje N, **Shustik C**, Lentzsch S, Lacy M, Mikhael J, Matous J, Vesole D, Chen M, Zaki MH, Jacques C, Yu Z, Anderson KC. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. *Blood*. 2014 Mar 20;123(12):1826-32. doi: 10.1182/blood-2013-11-538835. Epub 2014 Jan 13. Erratum in: *Blood*. 2014 May 15;123(20):3208-9.
- Chng WJ, Dispenzieri A, Chim CS, Fonseca R, Goldschmidt H, Lentzsch S, Munshi N, Palumbo A, Miguel JS, Sonneveld P, Cavo M, Usmani S, Durie BG, Avet-Loiseau H; **International Myeloma Working Group**. IMWG consensus on risk stratification in multiple myeloma. *Leukemia*. 2014 Feb;28(2):269-77. doi: 10.1038/leu.2013.247. Epub 2013 Aug 26. Review.

Emilie Soisson

- Hobson MA, **Soisson ET**, Davis SD, Parker W. Using the ACR CT accreditation phantom for routine image quality assurance on both CT and CBCT imaging systems in a radiotherapy environment. *J Appl Clin Med Phys*. 2014 Jul 8;15(4):4835. doi: 10.1120/jacmp.v15i4.4835.

Luis Souhami

- Rodrigues G, Lukka H, Warde P, Brundage M, **Souhami L**, Crook J, Cury F, Catton C, Mok G, Martin AG, Vigneault E, Morris J, Warner A, Maldonado SG, Pickles T; Genitourinary Radiation Oncologists of Canada (GUROC). The prostate cancer risk stratification project: database construction and risk stratification outcome analysis. *J Natl Compr Canc Netw*. 12:60-9, 2014.
- Cairncross JG, Wang M, Jenkins RB, Shaw EG, Giannini C, Brachman DG, Buckner JC, Fink KL, **Souhami L**, Laperriere NJ, Huse JT, Meht MP, Curran WJ. Benefit from PCV in Oligodendroglial Tumors is Associated with Mutation of *IDH*. *J Clin Oncol* 32:783-790, 2014.
- Turgeon G-A, **Souhami L**, Cury FL, Faria SL, Duclos M, Sturgeon J, Kassouf W. Hypofractionated IMRT in combined modality treatment for bladder preservation in elderly patients with invasive bladder cancer. *Int J Radiat Oncol Biol Phys* 88:326-331, 2014.
- Patel N, **Souhami L**, Mansure JJ, Duclos M, Aprikian A, Faria S, David M, Cury FL. Prostate-specific antigen bounce after high-dose-rate prostate brachytherapy and hypofractionated external beam radiotherapy. *Brachytherapy* 13:450-455, 2014.
- Turgeon G-A, **Souhami L**. Trimodality therapy for bladder-preservation in the elderly population with invasive bladder cancer. *Front Oncol* 4:1-9, 2014.
- Sperduto PW, Shanley R, Luo X, Andrews D, Werner-Wasik M, Valicenti R, Bahary JP, **Souhami L**, Won M, Mehta M. Secondary Analysis of RTOG 9508, a Phase 3 Randomized Trial of Whole-Brain Radiation Therapy Versus WBRT Plus Stereotactic Radiosurgery in Patients With 1-3 Brain Metastases; Poststratified by the Graded Prognostic Assessment (GPA). *Int J Radiat Oncol Biol Phys* 90:526-531, 2014.
- Owen S, **Souhami L**. The management of brain metastases in non-small cell lung cancer. *Frontiers in Oncology* 4:1-5, 2014.

Alan Spatz

1. Brimo F, Xu B, Scarlata E, Bégin LR, **Spatz A**, Salomon L, Zakaria AS, Ploussard G, Bladou F, Kassouf W, Tanguay S, Chevalier S, Ye H, Aprikian A Biopsy characteristics in men with a preoperative diagnosis of prostatic adenocarcinoma with high Gleason score (8-10) predict pathologic outcome in radical prostatectomy. *Hum Pathol*. 2014 Oct;45(10):2006-13. doi: 10.1016/j.humphath.2014.06.014. Epub 2014 Jul 2.
2. van Kempen LC, **Spatz A**. From biomarker development towards implementation of multidimensional biomarker panels in a clinical setting. *Mol Oncol*. 2014 Jun;8(4):781-2. doi: 10.1016/j.molonc.2014.05.002. Epub 2014 May 14.
3. Eggermont AM, **Spatz A**, Robert C. Cutaneous melanoma. *Lancet*. 2014 Mar 1;383(9919):816-27. doi: 10.1016/S0140-6736(13)60802-8. Epub 2013 Sep 19. Review.

Barry Stein

1. Lee L, Mata J, Ghitulescu GA, Boutros M, Charlebois P, **Stein B**, Liberman AS, Fried GM, Morin N, Carli F, Latimer E, Feldman LS. Cost-effectiveness of Enhanced Recovery Versus Conventional Perioperative Management for Colorectal Surgery. *Ann Surg*. 2014 Nov 3
2. Gillis C, Li C, Lee L, Awasthi R, Augustin B, Gamsa A, Liberman AS, **Stein B**, Charlebois P, Feldman LS, Carli F. Prehabilitation versus rehabilitation: a randomized control trial in patients undergoing colorectal resection for cancer. *Anesthesiology*. 2014 Nov;121(5):937-47
3. Melich G, Weber M, **Stein B**, Minutolo V, Arena M, Arena GO. Total sacrectomy for recurrent rectal cancer - A case report featuring technical details and potential pitfalls. *Int J Surg Case Rep*. 2014;5(7):403-7. doi: 10.1016/j.ijscr.2014.04.026. Epub 2014 Apr 30
4. Kakkar AK, Agnelli G, Fisher W, George D, Lassen MR, Mismetti P, Mouret P, Murphy J, Lawson F, Turpie AG; **SAVE-ABDO Investigators**. Preoperative enoxaparin versus postoperative semuloparin thromboprophylaxis in major abdominal surgery: a randomized controlled trial. *Ann Surg*. 2014 Jun;259(6):1073-9
5. Faria S, Kopek N, Hijal T, Liberman S, Charlebois P, **Stein B**, Meterissian S, Meguerditchian A, Fawaz Z, Artho G. Phase II trial of short-course radiotherapy followed by delayed surgery for locoregionally advanced rectal cancer. *Colorectal Dis*. 2014 Feb;16(2):O66-70

Jeremy Sturgeon

1. Turgeon GA, Souhami L, Cury FL, Faria SL, Duclos M, **Sturgeon J**, Kassouf W. Hypofractionated intensity modulated radiation therapy in combined modality treatment for bladder preservation in elderly patients with invasive bladder cancer. *Int J Radiat Oncol Biol Phys*. 2014 Feb 1;88(2):326-31. doi: 10.1016/j.ijrobp.2013.11.005.

Alasdair Syme

1. Tessier A, Yahya A, Larocque M, Fallone BG and Syme A (2014) Longitudinal evaluation of the metabolic response of a tumor xenograft model to single fraction radiation therapy using magnetic resonance spectroscopy. *Phys Med Biol* **59**: 5061 – 5072

Ivan Topisirovic

1. Zhua S, Rousseau P, Lauzona C, Gandin V, **Topisirovic I**, Autexier C (2014) Inactive C-terminal Telomerase Reverse Transcriptase Insertion Splicing Variants are Dominant-negative Inhibitors of Telomerase. *Biochimie* 2014 101:93-103. PMID: 24412622

2. Gandin V*, **Topisirovic I*** (2014) Co-translational mechanisms of quality control of newly synthesized polypeptides. *Translation* 2:e28109; <http://dx.doi.org/10.4161/trla.28109>. (*co-corresponding authors).
3. Miloslavski R, Cohen E, Avraham A, Iluz Y, Hayouka Z, Kasir J, Mudhasani R, Jones SN, Cybulski N, Rüegg MA, Larsson O, Gandin V, Rajakumar A, **Topisirovic I**, Meyuhas O (2014) Oxygen sufficiency controls TOP mRNA translation via the TSC-Rheb-mTOR pathway in a 4E-BP-independent manner. *Journal of Molecular Cell Biology*. 6(3):255-66. doi: 10.1093/jmcb/mju008. PMID: 24627160
4. Yamamoto, K, Gandin V, Sasaki M, McCracken S, Li W, Silvester JL, Elia AJ, Wang F, Wakutani Y, Alexandrova R, Oo YD, Mullen P, Inoue S, Isumi M, Lapin V, Haight J, Wakeham A, Shahinian A, Ikura M, **Topisirovic I**, Sonenberg N, Mak TW (2014) Largen: A Molecular Regulator of Mammalian Cell Size Control. *Mol. Cell*. Vol. 53, Issue 6, pp. 904-915. PMID: 24656129
5. Kyuen Im Y, La Selva R, Gandin V, Ha JR, Sabourin V, Sonenberg N, Pawson T, **Topisirovic I** and Ursini-Siegel J (2014) The ShcA adaptor activates AKT signaling to potentiate breast tumor angiogenesis by stimulating VEGF mRNA translation in a 4E-BP-dependent manner. *Oncogene* doi: 10.1038/onc.2014.110. PMID: 24837366
6. Piccirillo C, Bjur E, **Topisirovic I**, Sonenberg N and Larsson O (2014). Translational control of immune responses: from transcripts to translomes. *Nat. Immunol* 19;15(6):503-11. PMID: 24840981
7. Gandin V, Sikström K, Alain T, Morita M, McLaughlan S, Larsson O*, **Topisirovic I*** Polysome fractionation and analysis of mammalian translomes on a genome-wide scale. *JOVE* (87) doi: 10.3791/51455. PMID: 24893926 (*co-corresponding authors).
8. Gravel SP*, Hulea L*, Toban N*, Birman E, Blouin MJ, Zakikhani M, **Topisirovic I****, St-Pierre J**, Pollak M** (2014) Serine Deprivation enhances anti-tumour effects of biguanides. *Cancer Research* (*equally contributing authors; (**co-corresponding authors).
9. Cook D, Nuro E, Jones EV, Altimimi HF., Farmer WT, Gandin V, Hanna E, Zong R, Barbon A, Nelson DL, **Topisirovic I**, Rochford J, Stellwagen D, Béique JC, Murai KK (2014) Control of Long-Term Memory, Synaptic Plasticity and GluA2 Translation by FXR1P. *Cell Reports*
10. Topisirovic I*, Sonenberg N* (2014) Distinctive tRNA Repertoires in Proliferating versus Differentiating Cells. *Cell* 158(6):1238-9 PMID: 25215483. (*co-corresponding authors)
11. Furic L, Beardsley E, **Topisirovic I** (2014) The Role of eIF4E Phosphorylation Downstream of MAPK Pathway in Cancer Biology. In “Translation and Its Regulation in Cancer Biology and Medicine” Parsyan A (Ed.) Springer ISBN 978-94-017-9077-2.

Anna Towers

1. Tidhar D, Hodgson P, Shay C, **Towers A**. A lymphedema self-management programme: a report on 30 cases. *Physiotherapy Canada*, advance online article doi:10.3138/ptc.2013-46, 2014
2. Letellier ME, **Towers A**, Shimony A, Tidhar D. Breast cancer-related lymphedema: a randomized controlled pilot and feasibility study. *American journal of Physical Medicine and Rehabilitation* 93:751-763, 2014

3. Elizabeth Quinlan, Roanne Thomas, Thomas Hack, Winkle Kwan, Sue Tatemichi, **Anna Towers**, Andrea Tilley, Baukje Miedema. (2014). Lymphedema Trajectories Among Breast Cancer Survivors. *Journal of Lymphoedema*, 9 (1). 12-19.

Michel Tremblay

1. Hatzihristidis T, Desai N, Hutchins AP, Meng TC, **Tremblay ML**, Miranda-Saavedra D. A Drosophila-centric view of protein tyrosine phosphatases. *FEBS Lett.* 2015 Apr 13;589(9):951-966. doi: 10.1016/j.febslet.2015.03.005. Epub 2015 Mar 13. Review.
2. Lee D, Kraus A, Prins D, Groenendyk J, Aubry I, Liu WX, Li HD, Julien O, Touret N, Sykes BD, **Tremblay ML**, Michalak M. UBC9-dependent association between calnexin and protein tyrosine phosphatase 1B (PTP1B) at the endoplasmic reticulum. *J Biol Chem.* 2015 Feb 27;290(9):5725-38. doi: 10.1074/jbc.M114.635474. Epub 2015 Jan 13.
3. El-Assaad W, El-Kouhen K, Mohammad AH, Yang J, Morita M, Gamache I, Mamer O, Avizonis D, Hermance N, Kersten S, **Tremblay ML**, Kelliher MA, Teodoro JG. Deletion of the gene encoding G0/G 1 switch protein 2 (G0s2) alleviates high-fat-diet-induced weight gain and insulin resistance, and promotes browning of white adipose tissue in mice. *Diabetologia.* 2015 Jan;58(1):149-57. doi: 10.1007/s00125-014-3429-z. Epub 2014 Nov 9.
4. Nezvitsky L, **Tremblay ML**, Takano T, Papillon J, Cybulsky AV. Complement-mediated glomerular injury is reduced by inhibition of protein-tyrosine phosphatase 1B. *Am J Physiol Renal Physiol.* 2014 Sep 1;307(5):F634-47. doi: 10.1152/ajprenal.00191.2014. Epub 2014 Jul 23.
5. Moreno-Garcia MA, Pupavac M, Rosenblatt DS, **Tremblay ML**, Jerome-Majewska LA. The Mmchc gene is required for pre-implantation embryogenesis in the mouse. *Mol Genet Metab.* 2014 Jul;112(3):198-204. doi: 10.1016/j.ymgme.2014.05.002. Epub 2014 May 14.
6. Pike KA, Hutchins AP, Vinette V, Théberge JF, Sabbagh L, **Tremblay ML**, Miranda-Saavedra D. Protein tyrosine phosphatase 1B is a regulator of the interleukin-10-induced transcriptional program in macrophages. *Sci Signal.* 2014 May 6;7(324):ra43. doi: 10.1126/scisignal.2005020.
7. Hardy S, Uetani N, Wong N, Kostantin E, Labbé DP, Bégin LR, Mes-Masson A, Miranda-Saavedra D, **Tremblay ML**. The protein tyrosine phosphatase PRL-2 interacts with the magnesium transporter CNNM3 to promote oncogenesis. *Oncogene.* 2015 Feb 19;34(8):986-95. doi: 10.1038/onc.2014.33. Epub 2014 Mar 17.
8. Perron MD, Chowdhury S, Aubry I, Purisima E, **Tremblay ML**, Saragovi HU. Allosteric noncompetitive small molecule selective inhibitors of CD45 tyrosine phosphatase suppress T-cell receptor signals and inflammation in vivo. *Mol Pharmacol.* 2014 Apr;85(4):553-63. doi: 10.1124/mol.113.089847. Epub 2014 Jan 28.
9. Labbé DP, Nowak DG, Deblois G, Lessard L, Giguère V, Trotman LC, **Tremblay ML**. Prostate cancer genetic-susceptibility locus on chromosome 20q13 is amplified and coupled to androgen receptor-regulation in metastatic tumors. *Mol Cancer Res.* 2014 Feb;12(2):184-9. doi: 10.1158/1541-7786.MCR-13-0477. Epub 2013 Dec 30.
10. Xu L, **Tremblay ML**, Orrell KE, Leclerc J, Meng Q, Liu XQ, Rainey JK. Nanoparticle self-assembly by a highly stable recombinant spider wrapping silk protein subunit. *FEBS Lett.* 2013 Oct 1;587(19):3273-80. doi: 10.1016/j.febslet.2013.08.024. Epub 2013 Aug 28.

11. Bussi eres-Marmen S, Hutchins AP, Schirbel A, Rebert N, Tiganis T, Fiocchi C, Miranda-Saavedra D, **Tremblay ML**. Characterization of PTPN2 and its use as a biomarker. *Methods*. 2014 Jan 15;65(2):239-46. doi: 10.1016/j.ymeth.2013.08.020. Epub 2013 Aug 30.
12. Hatzihristidis T, Liu S, Prysycz L, Hutchins AP, Gabald on T, **Tremblay ML**, Miranda-Saavedra D. PTP-central: a comprehensive resource of protein tyrosine phosphatases in eukaryotic genomes. *Methods*. 2014 Jan 15;65(2):156-64. doi: 10.1016/j.ymeth.2013.07.031. Epub 2013 Jul 31

Josie Ursini-Siegel

1. Quigley D, Silwal-Pandit L, Dannenfelser R, Langerod A, Vollan HK, Vaske C, **Ursini-Siegel J**, Troyanskaya O, Chin SF, Caldas C, Balmain A, Borresen-Dale AL and Kristensen V. 2014. Lymphocyte invasion in IC10/basal-like breast tumors is associated with wildtype p53. *Molecular Cancer Research*, pii: molcanres.0387.2014
2. Bolt AM, Sabourin V, Molina MF, Police AM, Negro Silva LF, Plourde D, Lemaire M, **Ursini-Siegel J** and Mann KK. 2014. Tungsten targets the tumor microenvironment to enhance breast cancer metastasis. *Toxicological Sciences*, pii: kfu219.
3. Tofigh A, Suderman M, Paquet, ER, Livingstone J, Bertos N, Saleh SM, Zhao H, Souleimanova M, Cory S, Lesurf R, Shahalizadeh S, Garcia Lopez N, Riazalhosseini Y, Omeroglu A, **Ursini-Siegel J**, Park M, Dumeaux V and Hallett M. 2014. The prognostic ease and difficulty of invasive breast carcinoma. *Cell Reports*, 9: 129-42.
4. Hudson J, Ha, JR, Sabourin V, Ahn R, La Selva R, Livingstone J, Podmore L, Knight J, Forrest L, Beauchemin N, Hallett M, Park M and **Ursini-Siegel J**. 2014. p66ShcA promotes breast cancer plasticity by promoting an epithelial to mesenchymal transition. **Molecular and Cellular Biology**, 34: 3689-701 (*This article was selected for a press release from the American Society of Microbiology*).
5. Dumeaux V, **Ursini-Siegel J**, Flatberg A, Fjosne HE, Frantzen JO, Holmen MM, Rodegerdts E, Schlichting E and Lund E. 2015. Peripheral blood cells inform on the presence of breast cancer: A population based case-control study. *Int. J. Cancer*, 136: 656-67.
6. Young K. Im, Rachel La Selva, Valentina Gandin, Valerie Sabourin, Jacqueline Ha, Nahum Sonenberg, Tony Pawson, Ivan Topisirovic and **Josie Ursini-Siegel**. The ShcA adaptor protein activates AKT signaling to potentiate breast tumor angiogenesis by stimulating VEGF mRNA translation in a 4E-BP dependent manner. *Oncogene*, doi: 10.1038/onc.2014.110.

Marie Vanhuysse

1. Cools-Lartigue J, Jones D, Spicer J, Zourikian T, Rousseau M, Eckert E, Alcindor T, **Vanhuysse M**, Asselah J, Ferri LE. Management of Dysphagia in Esophageal Adenocarcinoma Patients Undergoing Neoadjuvant Chemotherapy: Can Invasive Tube Feeding be Avoided? *Ann Surg Oncol*. 2014 Dec 5. [Epub ahead of print]
2. Sudarshan M, Alcindor T, Ades S, Aloraini A, **Vanhuysse M**, Asselah J, David M, Frechette D, Brisson S, Thirlwell M, Ferri L. Survival and recurrence patterns after neoadjuvant docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophagogastric adenocarcinoma. *Ann Surg Oncol*. 2015 Jan;22(1):324-30. Epub 2014 Jul 15.
3. Madani A, Spicer J, Alcindor T, David M, **Vanhuysse M**, Asselah J, Mulder D, Ferri L. Clinical significance of incidental pulmonary nodules in esophageal cancer patients. *J Gastrointest Surg*. 2014 Feb;18(2):226-32.

4. Dragomir A, Dinea D, **Vanhuyse M**, Cury FL, Aprikian AG. Drug costs in the management of metastatic castration-resistant prostate cancer in Canada. *BMC Health Serv Res.* 2014 Jun 13;14:252.

Tsafir Vanounou

1. Wang Y, Bergman S, Piedimonte S, **Vanounou T**. Bridging the gap between open and minimally invasive pancreaticoduodenectomy: the hybrid approach. *Can J Surg.* 2014 Aug;57(4):263-70.

Antonio Vigano

1. **Vigano A**, Di Tomasso J, Kilgour RD, Trutschnigg B, Lucar E, Morais JA, Borod M. The Abridged Patient-Generated Subjective Global Assessment Is a Useful Tool for Early Detection and Characterization of Cancer Cachexia. *Journal of the Academy of Nutrition and Dietetics. J Acad Nutr Diet.* 2014 Jul;114(7):1088-98. doi: 10.1016/j.jand.2013.09.027. Epub 2014 Jan 24

Té Vuong

1. Néron S., Perez S., Benc R., Bellman A., Rosberger Z., **Vuong T**. The experience of pain and anxiety in rectal cancer patients during high-dose-rate brachytherapy. *Current Oncology* 21(1), p.e89-95, 2014
2. Niazi M.T., Mok G., Heravi M., Lee L., **Vuong T.**, Aloyz R., Panasci L., Muanza T. Effects of DNA-dependent protein kinase inhibition by NU7026 on DNA repair and cell survival in irradiated gastric cancer cell line N87. *Current Oncology* 21(2), 2014
3. **Vuong T.**, Garant A., Gallant F. Intensity Modulated radiation therapy for patients with rectal cancer. *Colorectal Cancer, Volume 3, No.3, Pages 235-238, June 2014*

Michael Witcher

1. Zhao T, Sun Q, del Rincon SV, Lovato A, Marques M and Witcher M. Gallotannin imposes S phase arrest in breast cancer cells and suppresses the growth of triple-negative tumors in vivo. *PLoS One.* 2014 Mar 21;9(3):e92853. doi: 10.1371/journal.pone.0092853.

Jian Hui Wu

1. Jiusheng Deng, Shala Yuan, Andrea Pennati, Jordan Murphy, **Jian Hui Wu**, David Lawson and *Jacques Galipeau. Engineered fusokine GIFT4 licenses the ability of B cells to trigger a tumoricidal T cell Response. *Cancer Res.* 2014, 74(15):4133-44.

Anthony Zeitouni

1. Henry M, Ho A, Lambert SD, Carnevale FA, Greenfield B, MacDonald C, Mlynarek A, **Zeitouni A**, Rosberger Z, Hier M, Black M, Kost K, Frenkiel S. Looking beyond disfigurement: the experience of patients with head and neck cancer. *J Palliat Care.* 2014 Spring;30(1):5-15.
2. Gurberg J, Bouganin N, Shenouda G, **Zeitouni A**. A case of recurrent anaplastic meningioma of the skull base with radiologic response to hydroxyurea. *J Neurol Surg Rep.* 2014 Aug;75(1):e52-5. doi: 10.1055/s-0033-1359300. Epub 2014 Apr 17.